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Abstract 
 
The role of vitamin D in bone health has been well established. Recent studies have provided 
a greater focus on the ways in which vitamin D and its metabolites have additional functions 
in the body that subsequently influence conditions such as common cancers, autoimmune 
diseases, cardiovascular diseases, depression and schizophrenia. Vitamin D is known to have 
more than 50 metabolites. The major circulating form in man is 25(OH)D3; having a long 
half-life, this compound is considered the principal biomarker therefore the best indicator of 
vitamin D status. Measuring 25(OH)D3 will, however, only provide an incomplete picture of 
vitamin D status that may or may not correlate with functions in disease. The 1,25-
dihydroxyvitamin D metabolites (1,25(OH)2D3 and 1,25(OH)2D2) are the most active forms 
that are responsible for bone health; evidence has now accumulated indicating its role in brain 
development. The 24,25-dihydroxyvitamin D metabolites (24,25(OH)2D3 and 24,25(OH)2D2) 
are responsible for bone fracture repair. The biological roles of vitamin D-sulfate compounds 
(D3-S, D2-S, 25(OH)D3-S and 25(OH)D2-S) are unclear to date, probably due to the lack of 
sufficiently sensitive assay methods to study them. It has been suggested that sulfated 
compounds are the storage forms of the non-conjugated metabolites,and may have similar 
potencies.  
 
Considering the above information, and given the diverse biological roles of vitamin D, it is 
important to accurately quantify as many forms as possible. Although widely used, 
immunoassay-based methods are not suitable for this purpose because of their inability to 
differentiate between some of these compounds. Liquid Chromatography-Tandem Mass 
Spectrometry (LC-MS/MS) has been the method of choice in recent years because of its high 
selectivity and sensitivity.  
 
This thesis describes the development and validation of an LC-MS/MS method for the 
quantitative analysis of 12 vitamin D compounds, specifically: D2, D3, 25(OH)D2, 25(OH)D3, 
24,25(OH)2D2, 24,25(OH)2D3, 1,25(OH)2D2, 1,25(OH)2D3, D3-S, D2-S, 25(OH)D3-S and 
25(OH)D2-S in biological fluids. During the initial method development, samples of human 
plasma and serum were compared. It was found that serum yielded higher concentrations of 
vitamin D compounds. Protein precipitation was compared with saponification method for 
extraction of vitamin D from biological fluids and found to be more effective. Vitamin D 
metabolites are known to have low ionisation efficiencies therefore produce weak signals in 
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MS detector. Pre-column derivatisation procedure using 4-phenyl-1,2,4-triazoline-3,5-dione, 
(PTAD) was attempted to enhance the ionisation efficiencies of 12 vitamin D compounds.  
However, this method failed to detect the sulfated compounds, except for traces of 
25(OH)D3-S and the derivatisation procedure proved unsuitable for sulfated compounds. 
 
The principal analytical challenge was that of extracting and chromatographing vitamin D 
compounds with very different lipophilicities in a single analysis procedure. The aim was 
therefore to overcome this challenge, and to simplify the method to be suitable for routine 
analysis. The compounds were extracted using online solid phase extraction (SPE) following 
serum protein precipitation with acetonitrile (without derivatisation). Pentafluorophenyl 
(PFP) stationary phase, used as the guard column / SPE trapping device, and as the analytical 
column enabled the extraction and separation of all 12 compounds in a single procedure. 
Both the extraction step and the separation step were optimised including the 
chromatographic separation of 25(OH)D3 from the inactive isomer 3-epi-25(OH)D3. The 
effects of mobile phase pH on separation and the effects of precipitant solvent on the protein 
precipitation efficiency were also investigated.  
 
Detection limits for all 12 compounds were in the picomole range when using a 500 µL 
sample volume. Recovery percentages ranged from 92% to 99%. A stable isotope labelled-
internal standard (SIL-IS) for each of the 12 vitamin D compounds was used as the co-eluting 
internal standard to correct for matrix effects in the MS detector as well as to correct for the 
procedural errors during sample extraction and clean up. In order to demonstrate the 
applicability of the proposed method, the validated method was then applied to assay for 
vitamin D compounds in mouse brain samples and donations of human serum samples 
collected from volunteers. 
 
Although the method developed and validated was simple, sensitive and accurate and 
amenable for the routine assay of 12 vitamin D compounds in serum, it was expensive to 
develop and implement because of the SIL-IS compounds required for each of the 12 vitamin 
D compounds. A standard addition method of calibration, instead of using SIL-IS, was 
proposed to overcome the matrix effects in MS detection. Since the conventional standard 
addition procedure does not address procedural errors, an additional internal standard (not co-
eluting) was included in the proposed method. The accuracy of this improved standard 
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addition method was validated through the determination of recovery, and by comparison 
with existing method SIL-IS method. Recoveries determined on human serum samples 
showed that the proposed method of standard addition yielded more accurate results than 
internal standardisation using SIL-IS. The precision of the proposed method of standard 
addition also proved superior to the conventional method of standard addition. 
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CHAPTER 1: LITERATURE REVIEW 
__________________________________________________________________________ 
1.1 Foreword 
Chapter 1 introduces the topic of vitamin D and its metabolism. This chapter also discusses 
the literature related to current research on analytical methods used to quantify vitamin D 
metabolites. The research hypothesis and aims of this thesis are also included. In this chapter, 
the general term of ‘vitamin D’ without a subscript refers to both the D2 and D3 metabolites 
as well as their hydroxylated metabolites, unless each substance was assigned by name. The 
topics are divided into main themes as shown below.  
 
1.2 Introduction 
Vitamins are a broad group of organic compounds that are minor, but essential, constituents 
of food diet, required for the normal growth, self-maintenance and functioning of both human 
and animal bodies. They have been categorised based on their solubility as being water-
soluble (which refers to vitamins B and C), as opposed to fat-soluble vitamins (FSVs) 
(particularly A, D, E and K) (1).  
 
Vitamin D is not a vitamin by strict definition because it can be produced by exposure of the 
skin to sunlight (2-4). Consequently, it is commonly regarded as the “sunshine vitamin”. In 
the case of humans, when sunlight is sufficient, a dietary requirement of vitamin D is not 
necessary. However, nutritional intake of vitamin D is required when sunlight is insufficient 
to meet daily needs. Vitamin D is comprised of six distinct compounds D2–D7, but only two 
compounds, D2 (ergocalciferol) and D3 (cholecalciferol) and their metabolites circulate in 
human biological fluids (5). In contrast to the other known vitamins crucial to human health, 
vitamin D is unusual due to the variety of sources available (6). Vitamin D2 is sourced from 
the UV irradiation of ergosterol (5), which is a steroid found in some plants but mostly in 
fungi such as shiitake mushrooms. Meanwhile, vitamin D3 is synthesised in human skin 
during skin exposure to solar radiation at 290-315 nm wavelength range from 7-
dehydrocholesterol (5, 7). Figure 1.1 shows the chemical structure and numbering of 7- 
dehydrocholesterol (8) as a parent compound of vitamin D. 
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Figure 1.1: Chemical structure of 7- dehydrocholesterol. [Adapted from reference (8)] 
 
 
Figure 1.2: Chemical structures of D2 and D3. [Adapted from reference (11)] 
 
 3 
 
During a heat-dependent process, pre-vitamin D3 (which is located in the skin) undergoes a 
rapid rearrangement of its double bonds to form vitamin D3 (9). Cleavage of the B ring of 7- 
dehydrocholesterol at the 9, 10-carbon bond as shown in Figure 1.2 yields pre-vitamin D3. 
Excessive exposure to sunlight degrades pre-vitamin D3 and vitamin D3 into inactive 
photoproducts (5). Hence, too much exposure to sunlight does not result in vitamin D3 
intoxication (10). The structures of vitamin D2 and vitamin D3 differ only at the C-17 side 
chain, which in vitamin D2 has a double bond and an additional methyl group at C-24 as 
shown in Figure 1.2 (11). 
 
Vitamin D compounds in the circulation are bound to the vitamin D binding protein 
(DBP)(12) and are also incorporated into chylomicrons which are transported via the 
lymphatic system into the venous circulation and then to the liver(13). A first oxidation step 
occurs in the liver, converting vitamin D3 and D2 into 25-hydroxyvitamin D3 [25(OH)D3] and 
25-hydroxyvitamin D2 [25(OH)D2], respectively. A further oxidation reaction takes place in 
the kidney and converts 25(OH)D3 and 25(OH)D2 to form the active metabolite either into 
1,25-dihydroxyvitamin D3 [1,25(OH)2D3] or 1,25-dihydroxyvitamin D2 [1,25(OH)2D2], 
respectively (14, 15). Alternatively, 25(OH)D3and 25(OH)D2 are thought to be catabolised 
into 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] and 24,25-dihydroxyvitamin D2 
[24,25(OH)2D2], respectively, and other oxidative metabolites followed by conjugation (16). 
25(OH)D3 is the major circulating metabolite of vitamin D3 and its 3-sulfate metabolite is 
postulated be a storage form (17).The biosynthesis and metabolism of D3 in humans are 
shown in the schematic illustrated in Figure 1.3 (18). 
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Figure 1.3: Biosynthesis and metabolism of D3 in man. [Modified from references (18, 19)] 
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Epimers are compounds that have the same molecular formula but different stereo 
chemistries. The structures of 25(OH)D3 and their respective 3-epimers differ only in the OH 
position on C-3. Initial research showed that the 3-epi-25(OH)D3 occurs only in infants and 
not adults (20). However, a study has also reported that the C-3 epimer was detected in adult 
serum in all samples, although the concentration was not listed (21). Collective measurement 
of the 3-epimers and 25(OH)D may contribute to an overestimation of the vitamin D forms 
and thereby adversely affect the outcome of clinical studies (22). Therefore, chromatographic 
separation of 25(OH)D3 from its 3-epi-25(OH)D3 isomer is necessary to enable quantification 
of each of these compounds, using liquid chromatography-mass spectrometry (LC-MS), since 
they have the same mass transitions. Although the biological function of 3-epi-25-
hydroxyvitamin D3 (3-epi-25(OH)D3) remains unknown, the first LC–MS method employing 
MS/MS detection for accurately capturing and separating the 3α epimer from the main 3β 
epimer and the subsequent quantification of 25(OH)D3was described in 2017 (23). This had 
the effect of, avoiding positive bias in vitamin D status analyses. However, the biological 
effects of 3-epimer of 1,25 dihydroxyvitamin D3 [3-epi-1,25 (OH)2D3], appear to be variable 
and it has been reported that this epimer is relatively inactive in vitro (24). It does not 
increase serum calcium but does suppress circulating parathyroid hormone (PTH) 
concentration in rats (25). Figure 1.4 shows the possible pathways of epimerisation for 
25(OH)D3 and 1,25(OH)2D3(26). 
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Figure 1.4: Epimerisation routes for 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3. 
The same reaction applies to 25(OH)D2, and 1,25(OH)2D2. Both 25(OH)D and 1,25(OH)2D 
can be epimerized at the carbon number 3 (C-3 position; epimeric centre). Epimers are non-
super imposable (or non-mirror images) that only differ in the configuration at one carbon 
atom. 3-Epi-25(OH)D can be converted to 3-epi-1,25-(OH)D by 1-hydroxylase. 
[Adapted from reference (26)] 
 
 
1.3 Chemistry and biological functions 
Vitamin D regulates the calcium and phosphorus levels in the blood by promoting their 
absorption from food in the intestines, and by stimulating reabsorption of calcium in the 
kidneys, thereby allowing normal mineralisation of bone. It is also essential for bone growth 
and bone re-modelling thus preventing rickets. Rickets is a condition associated with bone-
deformity due to inadequate mineralisation in growing bones (27, 28). It is an example of 
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known extreme vitamin D deficiency and can be prevented with adequate nutritional intake 
of vitamin D (27).  
 
Vitamin D is not only important for controlling bone health in children and adults, but also 
reportedly for biomedical advantages. These include reducing the risk of chronic diseases 
such as autoimmune diseases (29), common cancers (29-31), and multiple sclerosis (32). One 
meta-analysis of epidemiological studies has demonstrated a positive correlation between the 
intake of vitamin D and colorectal cancer prevention (33). The colon cancer risk was reduced 
by 50% with an intake of an additional 1000- 2000 international units per day (25-50 µg)(33). 
Most studies examining the relationships between vitamin D and disease or health focus on 
the main 25-hydroxyvitamin D3[25(OH)D3] metabolite, thus potentially overlooking the 
contributions and biological functions of other vitamin D metabolites, the crucial roles of 
several of these which have been previously demonstrated (34). Considering the above 
information and the respective studies recognising the role of vitamin D in the prevention of 
these diseases, an increased interest has been generated in quantifying vitamin D levels in 
human serum or plasma. Therefore, advances in our understanding of the relationship 
between vitamin D status and health are subject to our capacity to measure the precise 
vitamin D status. 
 
In the following section, each vitamin D compound and their biological functions were 
described and LC/MS methodologies for quantitative analysis of vitamin D compounds was 
discussed including D3, D2, 25(OH)D3, 25(OH)D2, 1,25(OH)2D3, 1,25(OH)2D2, 
24,25(OH)2D3, 24,25(OH)2D2 as well as conjugation products such as sulfate metabolites (D3-
S, D2-S, 25(OH)D3-S, 25(OH)D2-S). 
 
1.3.1  D3 and D2 
As mentioned above, vitamin D occurs in man as two forms: D3 and D2. Both vitamins D2 
and D3 are biologically inactive and have half-lives of approximately 24 h. Accordingly, the 
measurements of these compounds in serum do not reflect the physiologically relevant levels 
of vitamin D in the body (35). However, the requirement for vitamin D is normally met by its 
synthesis in the skin. The vitally important vitamin D3 and D2 synthesis is induced by natural 
UV irradiation in the epidermis. Therefore, both D3 and D2 play an important role in the 
regulation of the systemic calcium and phosphorus from the gastrointestinal tract and in the 
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treatment of rickets (36, 37). Non-metabolised vitamin D3 and D2 are stored in adipose tissue 
and skeletal muscle, then released during period of vitamin D3 or D2 deprivation for use in 
bone metabolism (11). 
 
Vitamin D3 and D2 compounds, as precursor compounds have rarely been measured except 
for a few studies concerned with breastfeeding mothers (38). In animal studies, the potency of 
vitamin D3 was found to be lower than vitamin D2 when the animal is nocturnal and/or when 
its diet is mainly plant-based (11). In monkeys, the concentrations of serum 25(OH)D3 
increased two-fold to three-fold after intake of vitamin D3 compared to that generated by 
similar amounts of vitamin D2(39). Similarly, in rats vitamin D3 was found to be more 
effective (40, 41). Meanwhile, studies conducted on birds demonstrated vitamin D2 to be only 
one-tenth as effective as vitamin D3 at increasing plasma concentrations of 25(OH)D3 (42). 
 
Although, in humans, vitamins D2 and D3 are comparable in their metabolism and the 
potency of their metabolites (43), there has been debate over the effectiveness of vitamin D2 
compared to D3. Some studies report that D2 is less effective than D3 at raising the 25(OH)D3 
or 25(OH)D2 concentrations in blood (43-45). These differences have been largely explained 
on the basis of the relative binding affinity of vitamin D and its metabolites to the plasma 
vitamin D binding protein (DBP). This difference in the binding ability is potentially 
explained by the presence of a methyl group at carbon 24 in the D2 molecule as shown in 
Figure 1.2 (46). 
 
1.3.2 25(OH)D3 and 25(OH)D2 
Although, there is no universal agreement, vitamin D nutritional status is defined by most 
experts with reference to the 25(OH)D [25(OH)D3 and 25(OH)D2] concentration in serum or 
plasma (31, 47). However, 25(OH)D is considered to be the best biomarker of vitamin D 
status because this compound has been found at higher concentration in serum and has a three 
week half-life which allows a more robust estimate of vitamin D status from both dietary 
intake and UV irradiation (35). As 25(OH)D is converted to the active form in the kidney, it 
is a poor marker for vitamin D status in kidney disease patients (48). A low level of 25(OH)D 
may be related with different cardiovascular risk factors, such as: hyperglycaemia; insulin 
resistance, Type 2 diabetes, dyslipidaemia and high blood pressure (49-52). 
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Most experts agree that 25(OH)D concentration above 30 ng/mL (75 nmol/L) are considered 
to be normal and sufficient (53-57), whereas a concentration of 21–29 ng/mL (51–74 nmol/L) 
is considered to indicate insufficiency and below 20 ng/mL (50 nmol/L) (58-60) is an 
indication of vitamin D deficiency. Severe deficiency leads to rickets in children and 
osteomalacia in adults in much the same way as calcium deficiency (5). Contrary to the case 
with hypovitaminosis, vitamin D intoxication is observed when serum levels of 25(OH D3 are 
greater than 150 ng/mL (374 nmol/L) (5) and are associated with hypercalcemia and 
hyperphosphatemia (57, 61-64). With the use of such definitions, it has been estimated that 
one billion people worldwide have either a deficiency or in insufficiency of vitamin D(65). 
 
1.3.3 1,25(OH)2D3 and 1,25(OH)2D2 
1,25(OH)2D3 and 1,25(OH)2D2 are biologically active forms of vitamin D converted from 
25(OH)D3 and 25(OH)D2 in the liver. Although a number of research papers have reported 
that serum levels of 1,25(OH)2D3 and 1,25(OH)2D2 do not reflect the body’s storage and are 
not useful for determining vitamin D status, one of the functions of 1,25(OH)2D3 and 
1,25(OH)2D2 is to maintain the content of calcium and phosphorus in the blood (8). 
1,25(OH)2D stimulates the absorption of dietary calcium through the intestines and 
participates in the incorporation of calcium into the skeleton (66). It was discovered, that 
when the presence of 1,25(OH)2D, it will increase the absorption of renal calcium and of 
intestinal calcium and phosphorus (29, 63) 
 
The respective levels of 1,25(OH)2D3 and 1,25(OH)2D2 are not adequate to evaluate the 
nutritional status of vitamin D due to their short half-life in serum of only 4 h (35). 
Furthermore, in routine analysis, 1,25(OH)2D3 is a challenging analyte since its concentration 
in human serum is extremely low at picogram levels [normal range: 25-70pg/mL (65-182 
pmol/L)] (11).The first assay technique for 1,25(OH)2D3 and 1,25(OH)2D2, reported by 
Brumbaugh et al. (67) in 1974, utilised the chick intestinal cytosol-chromatin receptor 
system. The measurement of 1,25(OH)2D3 and 1,25(OH)2D2 levels in serum are useful in 
evaluating patients with chronic renal failure (67, 68), hypoparathyroidism, 
hyperphosphatemia, hypomagnesaemia, rickets granulomatous diseases or lymphoma (68, 
69) and in the treatment of psoriasis (70). 
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1.3.4 24,25(OH)2D3 and 24,25(OH)2D2 
The serum concentrations of 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] are also of potential 
interest when attempting to understand the in vivo kinetics of 25(OH)D3 in serum. The 
metabolites 24,25(OH)2D3 and 24,25(OH)2D2were originally considered to be inactive and 
serving little purpose other than redirecting the metabolism of 25(OH)D3 and 25(OH)D2 
respectively, but were later found to play a crucial role in healing processes in bone formation 
(71) and fracture repair (11). Furthermore, incidence of increased bone volume was reported 
(72). It has been argued that the concentrations of 24,25(OH)2D3 and 24,25(OH)2D2in the 
circulation have the potential to be both clinically valuable indicators but also potential 
nuisances as analytical interferences at the same time, thereby underlining the significance of 
their definitive measurement in plasma or serum (73). The normal plasma/serum 
concentration of 24,25(OH)2D3 in humans ranges are approximately 1-4 ng/mL (19). 
Attempts to increase the ionisation efficiency for mass spectrometry have been reported in 
several studies as part of methods for multiple vitamin D compounds (19, 74). However, in a 
recent study in 2017, Dowling et al.(75) improved the accuracy of measuring both 3-epi-
25(OH)D3 and 24R,25(OH)2D3 in serum without the use of a derivatisation agent. The most 
common method used to measure vitamin D, immunoassay, is not capable of differentiating 
between 24,25(OH)2D3 and 25(OH)D3(76).  
 
1.3.5 25(OH)D3-Sulfate, 25(OH)D2-Sulfate, D3-Sulfate and D2-Sulfate 
In 1985, one study first identified the existence of 25-hydroxyvitamin D3-sulfate 
[25(OH)D3S] in human plasma (77). Although the biological role of 25(OH)D3-S is still not 
fully understood, there is an assumption that it might be a storage form of vitamin D3(78, 79). 
The circulating levels of this metabolite were found to be similar to or exceeding that of the 
major circulating form (25(OH)D3) in adults and infants, respectively (77, 80). Therefore, it 
has been suggested that conjugation of vitamin D with sulphate plays an important role in 
vitamin D metabolism. It is also considered that the quantification of 25(OH)D3-S in 
plasma/serum was viewed as being important in researching its significance in pregnant 
women and newborns as well as for its assessment of vitamin D status, especially in infants 
(78).  
Sasashi et al. suggested that vitamin D2-S has approximately the same antirachitic potency as 
vitamin D2(81). Miravet et al. further reported potent biological activity of the vitamin D3-
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Sand D3 (82).However, the results from a study by Cancela et al. shows that vitamin D3-S is 
clearly less active than the same dose of free vitamin D3in promoting normal mineral 
homeostasis and bone mineralisation in rats during the lactation period(83). In 2015, a 
method using LC with MS detection has been reported for the quantification of four sulfated 
forms of vitamin D: vitamins D2 and D3-sulfate (D2-S and D3-S) and 25-hydroxyvitamin D2 
and 25-hydroxyvitamin D3-sulfate (25(OH)D2-S and 25(OH)D3-S) in human serum and 
breastmilk (84). Figure 1.5 shows the chemical structures for vitamin D-sulfate. 
  
Figure 1.5: Chemical structures of 25(OH)D3-S, 25(OH)D2-S, D3-S and D2-S. The sulfates 
are shown as the sulfate anion 
 
1.4  Sources of vitamin D 
One of the main sources of vitamin D for most humans is sun exposure (62, 85). Circulating 
vitamin D3 levels are largely dependent on the action of UV light. As mentioned in the 
introduction of vitamin D above, people who are exposed to sunlight every day have never 
had to be concerned about vitamin D intoxication because once pre-vitamin D3 and vitamin 
D3 are made in the skin they can absorb UVB and UVA radiation. This results in their 
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conversion to a wide variety of photoproducts that have little, if any, effect on calcium 
metabolism (86, 87). This is the likely explanation for no reported cases of vitamin D 
intoxication due to excessive exposure to either sunlight (88) or UVB radiation from artificial 
sources such as tanning beds (87). However, the total of the vitamin biosynthesised for each 
day is affected by many factors, including: ultraviolet radiation (sunlight) exposure on the 
skin, the season of the year, clothing, and skin melanin pigments.  
 
Humans also obtain vitamin D from their diet and dietary supplements. Vitamin D(D 
represents either D2 or D3) is derived from fortified foods, tuna, sardines, salmon, mackerel, 
egg yolk, cod liver oil, mushrooms and fish ingested from one’s diet as shown in Table 1.1 
(5). A naturally oily fish such as salmon contains significant amounts of vitamin D3. It is an 
excellent source of vitamin D3 that could prevent vitamin D deficiency (63).  
 
There are relatively few sources of vitamin D2, and these are mainly found in plants. D2 is 
produced through the ultraviolet irradiation of ergosterol in plants and is also found in foods 
such as shiitake, wild mushrooms and egg yolks. In many countries, vitamin D2 
(ergocalciferol) is used for the purpose of fortification; this is derived from plant sources 
(89). In addition, supplements are another source of vitamin D in the body which could help 
those at risk of vitamin D deficiency due to insufficient sun exposure and/or poor dietary 
intake. Vitamin D3 is the form mostly used in supplements; less frequently for vitamin D2. 
Both can be accessed as over-the-counter vitamin D supplements. It is very important to have 
early identification for those individuals who are vitamin D deficient so that adequate 
supplementation can be prescribed as early as possible. However, studied by Saande et 
al.(90) demonstrated that dietary consumption of whole eggs may be more effective than 
supplemental cholecalciferol in maintaining normal circulating 25(OH)D concentrations. 
 
Metabolically, hypervitaminosis D is characterised by high levels of 25-hydroxyvitamin D3 
and 25-hydroxyvitamin D2 in serum (61). Toxicity (hypervitaminosis D) caused by over- 
fortification of food is unusual; it does exist, however, and has been reported as accidental 
vitamin D intoxication (61, 91). A previous study discovered a case of 35 hypervitaminotic 
patients having hypercalcaemia resulting from chronic ingestion of accidentally over-fortified 
milk (61). However, hypervitaminosis D could also occur in patients taking prescribed 
vitamin D supplements (92); increasing age was related to the development of 
hypervitaminosis D. It was predicted that connection to age-related decrease in renal function 
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may be relevant (93). The consequences of this case also highlight the importance of 
observing carefully the limits of vitamin D supplementation. Prolonged hypervitaminosis D 
can cause calcium deposition in the soft tissues (especially the kidneys and heart); this may 
affect the central nervous system and in severe cases can result in death (94-97).  
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Table 1.1:Dietary sources of Vitamin D2 and D3(5) 
 
Source Vitamin D Vitamin D Content* 
Fortified milk, usually vitamin D3 About 100 IU/8 oz (2.5 μg/8 oz) 
Fortified orange juice, vitamin D3 About 100 IU/8 oz (2.5 μg/8 oz) 
Infant formulas, vitamin D3 About 100 IU/8 oz (2.5 μg/8 oz) 
Fortified yogurts, usually vitamin D3 About 100 IU/8 oz (2.5 μg/8 oz) 
Fortified butter, usually vitamin D3 About 50 IU/3.5 oz (1.3 μg/3.5 oz) 
Fortified margarine, usually vitamin D3 About 430 IU/3.5 oz (10.8 μg/3.5 oz) 
Fortified cheeses, usually vitamin D3 About 100 IU/3 oz (2.5 μg/3 oz) 
Fortified breakfast cereals, usually vitamin D3 About100 IU/serving (2.5 μg/serving) 
Egg yolk, vitamin D3 or D2 About20 IU/yolk (0.5 μg /yolk) 
Tuna, canned, vitamin D3 About 230 IU/3.5 oz (5.8 μg/3.6oz) 
Mackerel, canned, vitamin D3 About250 IU/3.5 oz (6.3 μg/3.5 oz ) 
Sardines, canned, vitamin D3 About300 IU/3.5 oz (7.5 μg/3.5 oz) 
Salmon, farmed, vitamin D3orD2 About 100–250 IU/3.5 oz (2.5- 6.3 μg/3.5 oz) 
Salmon, wild, vitamin D3 About 600–1000 IU/3.5 oz (15- 25 μg/3.5 oz) 
Shiitake mushrooms, sun-dried, vitamin D2 About 1,600 IU/3.5 oz (40 μg /3.5 oz) 
Shiitake mushrooms, fresh, vitamin D2 About 100 IU/3.5 oz (2.5 μg /3.5 oz) 
 
*IU denotes international unit, which equals 0.025 µg or 65pmol. The unit definition of the 
active metabolite calcitriol was set to be equivalent in terms molar to that of the parent 
vitamin D3(2). 
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1.5  Causes of vitamin D deficiency 
It is widely recognised that, the major source of vitamin D for humans is exposure to 
sunlight. However, sun exposure also causes 99% of non-melanoma skin cancers and 95% of 
melanoma cases in Australia (98). Thus, a balance of sunshine is required to allow sufficient 
sun exposure so as to maintain adequate vitamin D3production but to minimise the risk of 
skin cancer. No paediatric data from Australian or New Zealand are available concerning the 
duration of UVB radiation exposure required to maintain adequate levels of vitamin D (99). 
 
Populations at high latitudes, together with dark-skinned persons, veiled persons and 
pregnant women also have a high risk of vitamin D deficiency (99). Anything that interferes 
with the penetration of UVB radiation into the skin will affect the cutaneous synthesis of 
vitamin D3 (86). A sunscreen prevents UV-B and some UV-A light from entering the skin 
and sunscreen with a sun protection factor SPF 8 can prevent and decrease vitamin D3 
synthetic capacity by 95%, while SPF 15 can decrease it by 98%(100). Differences in vitamin 
D levels related to season are also highly significant; there is less occurrence of vitamin D3 
synthesis during the winter time as well as in the early morning and late afternoon (101). The 
amount of human body that is exposed to the sun is associated with marked differences in 
vitamin D synthesis (102). At least 20% of the skin should be uncovered to UV-B in order for 
blood vitamin D concentrations to increase (103). In Saudi Arabia, women and children wear 
traditional clothing as their routine, and therefore, are at greatest risk of vitamin D deficiency 
(103). The practice of purdah, whereby all skin is covered and prevented from being exposed 
to sunlight, places those who practice it at a high risk of vitamin D deficiency. This explains 
why, in the sunniest areas of the world, vitamin D deficiency is very common in both 
children and adults (104-106). 
 
Melanin is extremely efficient in absorbing UVB radiation, and, thus, increased skin 
pigmentation markedly reduces vitamin D3 synthesis (107). Overall, an Asian Indian person 
requires a longer duration of sun exposure a day than light-skinned person for a similar 
response (three-fold; compared to a black person at six to ten-fold) to achieve equivalent 
vitamin D concentrations (107, 108). Mothers who were experiencing vitamin D deficiency 
through pregnancy and exclusively breastfed dark-skinned infants appear to be at particularly 
high risk of vitamin D deficiency and, additionally, their infants (103). 
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There are several factors might be related to low levels of vitamin D amongst the elderly; 
they frequently do not go out into the sunshine for sufficient periods and aging also lowers 
both the amount of 7-dehydrocholesterol in the skin and therefore their the capacity for 
vitamin D production (109, 110). In addition, vitamin D deficiency can also be caused by 
several factors including (a) deprivation of sunlight, (b) avoidance of dairy products, due 
either to low socioeconomic status or intolerance due to lactase deficiency, and (c) intestinal 
malabsorption of lipophilic vitamin D (110). 
 
A low intake in food may be from individual choice or from necessity in societies too poor to 
afford foods containing vitamin D. A reduced intake of fortified milk is common among 
young women of motherhood age, which results in decreased vitamin D concentrations in the 
blood (103). Vitamin D is fat-soluble and therefore it is readily taken up by fat cells. Hence, 
obesity has been linked with vitamin D deficiency, and it is believed to be due to the 
sequestration of vitamin D by the large body fat pool (111, 112). Medications including 
anti-seizure medications, glucocorticoids and fat malabsorption are also common causes of 
deficiency (113). 
 
1.6  Consequences of vitamin D deficiency 
A study by Holick (65) found that the burning of coal caused severe pollution in northern 
Europe and was the trigger point whereby people started to become concerned about vitamin 
D deficiency and its health consequences in humans. In addition, industrial structures and 
houses in close proximity insulate children from sun exposure, resulting in the bone-
deforming disease commonly known as rickets (65). In addition to skeletal effects, evidence 
also suggests that vitamin D deficiency can be related to the non-skeletal disorders mentioned 
below. 
 
1.6.1 Skeletal 
Vitamin D deficiency causes muscle weakness has been associated with vitamin D deficiency 
(31, 62, 114). Skeletal muscles have a vitamin D receptor and require vitamin D for 
maximum function (62, 115, 116). In adults, it can cause a skeletal mineralisation defect; the 
non-mineralised osteoid provides little structural support for the periosteal covering. As a 
result, patients with osteomalacia often complain of global bone discomfort along with aches 
and pains in their joints and muscles (117). In addition, the effects of rickets in young women 
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may mean that they cannot deliver babies vaginally because of a deformed pelvis and 
consequently often need to have caesarean sections to deliver children (86).  
 
1.6.2 Non-skeletal 
The vitamin D receptor (VDR) is also present in many body tissues (118, 119), suggesting 
that vitamin D has non-skeletal actions (60). Low levels of 25(OH)D3 may be related with 
different risk factors, such as: various cancers (33, 120, 121), Type 1 (122) and Type II 
diabetes (123, 124), multiple sclerosis (125-127) and melanoma (128). An optimal level of 
vitamin D may also have a positive effect on decreasing the risk of specifically: obesity, 
wheezing, allergy asthma, mental disease, depression (129), schizophrenia, infections 
(pulmonary and urinary), kidney failure and hypertension, respectively (35). Figure 1.6 
shows a schematic representation of the major causes of vitamin D deficiency and potential 
health consequences, including: adult onset diabetes mellitus (AODM); coronary heart 
disease (CHD); forced expiratory volume in 1s (FEV1); highly active antiretroviral therapy 
(HAART); high blood pressure (HBP); multiple sclerosis (MS); rheumatoid arthritis (RA); 
tuberculosis (TB); as well as urinary tract infection (URI) (130). 
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Figure 1.6:A schematic representation of the major causes of vitamin D deficiency.AODM, 
adult onset diabetes mellitus; CHD, coronary heart disease; FEV1, forced expiratory volume 
in 1s; HAART, highly active antiretroviral therapy; HBP, high blood pressure; MS, multiple 
sclerosis; RA, rheumatoid arthritis; TB, tuberculosis; URI, urinary tract infection. 
[Adapted from reference (130)] 
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1.7 Treatment of vitamin D deficiency 
Most experts have suggested that the daily maintenance dose of vitamin D varies by age; 
children and adults alike require 800–1000 IU (20-25 µg) of vitamin D3 to satisfy the body’s 
vitamin D requirement, when sunlight is unable to provide it (31, 62, 131, 132). Only few 
natural dietary sources contain vitamin D, hence it is important to obtain vitamin D 
replacement from supplements (133). Thus, taking a vitamin D supplement and taking 
advantage of the beneficial effect of sun exposure will help guarantee vitamin D sufficiency 
for maximising bone health and possibly for other health benefits (134).  
 
When a person is vitamin D deficient, 50 000 IU/week of vitamin D for eight weeks is often 
effective (5, 58) compared to 1000 IU/day. Higher doses may be required for patients who 
are severely deficient or with intestinal fat malabsorption syndrome and obesity to sustain 
serum level of 25(OH)D3>30 ng/mL (75 nmol/L) (5, 112). 
 
To correct vitamin D deficiency in infants and children, vitamin D supplementation should be 
administered as follows: 200 IU/day (5 µg/day) for infants and children of all ages.  
However, there are also higher levels, such as: 1000 IU/day (25 µg/day) for children 0–1 yr, 
2000 IU/day(50 µg/day) for children 1–19yrs and older (135). The Institute of Medicine 
recommended that all children (also endorsed by the American Academy of Pediatrics) and 
adults up to the age of 50 years require 200 IU vitamin D/day and adults aged 51–70 and 71 
yrs old need 400 and 600 IU vitamin D/day (136). After correction of their vitamin D status 
with an oral doses of vitamin D, patients should have a repeat test of their 25(OH)D3 level to 
confirm that they are in the normal range. If the 25(OH)D3 concentration remains persistently 
low despite several attempts at correction with oral vitamin D, a trial of UVB light therapy 
(i.e. by tanning lamps) may be considered in order to treating rickets, as demonstrated by a 
marked increase in the mineralisation of the skeleton (137). 
 
1.8 Plasma and serum samples 
Blood (plasma or serum) are widely used matrices in clinical and biological studies and are 
frequently used to assist in the diagnosis of cases of vitamin D deficiency. Both plasma and 
serum are aqueous solutions (about 95% w/v water) containing a variety of substances. These 
include: proteins and peptides (such as albumins, globulins, lipoproteins, enzymes and 
hormones), nutrients (such as carbohydrates, lipids and amino acids), electrolytes, organic 
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wastes and a variety of other small organic molecules either suspended or dissolved in them. 
Compositions of plasma and serum in terms of molecules appear to be relatively similar 
(based on current analytical techniques) (138).  
 
Both plasma and serum are derived from full blood that has undergone different biochemical 
processes after blood collection. Plasma is obtained from a blood sample after anti-coagulants 
are introduced. After centrifuging the sample, three layers are observed and the least dense 
(non-cellular) portion is plasma. If the blood is allowed to clot and no anticoagulant is added, 
the upper layer of the fluid is called serum; serum is less viscous than plasma and lacks 
fibrinogen, prothrombin and other clotting protein (139). Plasma is a straw-coloured liquid in 
which blood cells are suspended, comprising approximately 50–55% of blood volume, with 
blood cells (erythrocytes, leukocytes and platelets) accounting for the remaining portion 
(140). 
 
There is limited evidence that different collecting procedures and the coagulation cascade can 
influence concentrations of both proteins and metabolites in these matrices. One concern is 
the effect of anticoagulants on LC–MS/MS assay performance. One study demonstrated that 
different sample matrices, serum, heparin or K2-EDTA coagulated plasma, did not cause 
significant variation in 25(OH)D2 and 25(OH)D3 quantification (141). A recent study using a 
SPE-LC/MS method, confirmed that vitamin D3, 24,25-dihydroxyvitamin D3 and 25-
hydroxyvitamin D3 levels in plasma and serum were similar, while levels of 1,25-
dihydroxyvitamin D3 were significantly different, being higher in plasma than in serum (142).  
 
1.9 Analytical methods for quantification of vitamin D compounds 
A wide variety of methodologies have been developed for the quantification of vitamin D 
metabolites in serum/plasma samples. A literature review identified approximately 90 
publications on the measurement of vitamin D within the period 2008 – 2012 (143). The 
analysis of vitamin D compounds is further complicated by their compound structural 
similarity, the predominantly hydrophobic/lipophilic nature of vitamin D compounds and the 
hydrophilic nature of some of the metabolites, and their instability in the presence of heat or 
UV light. Accordingly, analysis requires selective and rapid analytical methods. Among 
these, there are two main types of methods which are used routinely, namely: competitive 
immunoassays and methods based on chromatographic separation followed by non-
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immunological direct detection (HPLC-UV and LC–MS/MS). Immunoassays are frequently 
commercial kits and include radioimmunoassay (RIA), enzyme-linked immunoassay 
(ELISA), chemiluminescent linked immunoassay (CLIA), and electro-chemiluminescent 
(ECL) methods. Immunoassays are readily automated, suitable for high throughput and do 
not require high level technical skills to obtain satisfactory results. However, the major 
disadvantage is that of specificity as immunoassays are not able to separate 25(OH)D2 and 
25(OH)D3 metabolites on an equimolar basis. In addition, these methods are unable to detect 
25(OH)D2, thus making them unsuitable for monitoring any patient on 25(OH)D2 
supplementation (144-147). From the results studied by Cavalier et al., in method such as 
Diasorin RIA, Diasorin Liaison, Roche Elecsys and HPLC (35), the uncertainty used to 
determine 25(OH)D3 was found to be up to 20%. The authors concluded that a physician 
should ensure that patients’ results are ≥ 100 nmol/L if the normal status level is considered ≥ 
80 nmol/L (35). 
 
Previously, liquid chromatography (LC) with ultraviolet detection (UV) has been a common 
technique for measuring vitamin D. Unfortunately, lack of specificity in UV detection and 
high limits of detection (LOD) required high sample volumes of assessment of circulating 
vitamin D metabolites present at low concentrations (148). Liquid chromatography- tandem 
mass spectrometry (LC- MS/MS) is currently the most powerful tool for the analysis of 
vitamin D compounds in biological fluids. In recent years, LC-MS/MS has been established 
as the technique of choice for vitamin D analysis because it conveys both high specificity and 
sensitivity (149). LC-MS methods allow the separation of compounds based on their 
polarities, ionisation behaviours, and mass to- charge (m/z) ratios and can offer very low 
limits of quantitation. LC-MS methods are also excellent for targeting the identification of 
low abundance metabolites over a wide polarity range. The low chemical reactivity of these 
compounds together with their low concentration in human systematic circulation, 
particularly for 1,25(OH)2D3 (150) are the limiting factors for the development of new 
analytical methods for their determination. In order to study the patho-biological role of 
vitamin compounds including the potentially important low-abundance species, it is 
important that the concentrations are determined. Moreover, LC-MS/MS is able to measure 
25(OH)D2 and 25(OH)D3 independently with good recoveries (151). The ability to measure 
25(OH)D2 and 25(OH)D3 separately has been the main criterion distinguishing LC- MS/MS 
method from immunoassays and the HPLC- UV method. However, measurements of vitamin 
D species from biological fluids such as plasma or serum using mass spectrometry are not 
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without challenges. These challenges include: abundant isobaric and isomeric interferences in 
serum or plasma (152), low ionisation efficiencies for mass spectrometric analyses (153) and 
matrix effects in MS detection (154). Moreover, the use of LC- MS/MS equipment is costly 
and requires significant technical expertise (155). However, LC–MS/MS has more strengths 
and fewer weaknesses as identified by users compared with other methods.  
 
A very sensitive analytical method is required to quantify the different vitamin D metabolites 
in relevant human biological fluids and, simultaneously, be selective enough to differentiate 
the numerous metabolic species (34). Therefore, increasing the selectivity and sensitivity for 
determination of vitamin D metabolites has been the aim of various methods and has focused 
on sample clean-up/extraction and analyte concentration prior to determination.  
 
1.10  Sample preparation/extraction 
Analysing lipid soluble compounds such as vitamin D metabolites in biological fluid samples 
provides a great challenge to ensure an efficient sample clean-up and to remove other 
interfering substances prior to analyte separation and/or detection (155). Establishing an 
appropriate extraction method for vitamin D is crucial as it cannot be assessed by the 
validation process (143). Therefore, the release of the vitamin from the sample matrix is a 
crucial step that affects the sensitivity and reproducibility of the analytical process.  
 
Ideally, the extraction method must be capable of dislodging the entire vitamin content from 
the matrix before analysis. One way of assessing the efficiency of extraction is to compare 
the results from a variety of extraction methods, as was accomplished in a recent study: six 
different vitamin D assay methods were compared and the results showed high variability 
illustrating inconsistency in the extent of vitamin D release from the matrix (156). Most 
methods performed poorly with samples from pregnant mothers having higher amounts of 
vitamin D binding proteins. When vitamin D release from such proteins is incomplete, falsely 
low estimates for in vivo vitamin D status are obtained. The above study included both 
chromatographic and immunoassay methods as both use some form of extraction to release 
the vitamin, although in kit-based immunoassays this extraction step is less obvious. Most 
immunoassays use protein precipitation either by using common precipitant solvents or 
through reagents provided by suppliers of the kit.  
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Traditionally, saponification has been used for the extraction of vitamin D from foodstuffs 
including milk, and protein precipitation is used for the same in plasma and serum. There 
have been only a limited number of instances where saponification has been used for serum 
and plasma (143).  
 
Liquid-liquid extraction (LLE) and solid phase extraction (SPE) also have been used as 
extraction/sample clean-up procedures in vitamin D assays analyses after the release from 
matrix components such as protein and fat. 
 
1.10.1 Protein Precipitation 
Protein precipitation has been frequently used as a fast sample clean-up extraction procedure 
due to its simplicity by which to release proteins from biological fluids (143, 157). 
Precipitation is useful as it can be employed to denature the protein, destroying its drug-
binding ability depending on the binding mechanism (158). In order to quantify a drug in a 
serum or plasma sample, it is often necessary to disrupt the protein–drug binding so that the 
total amount of the drug can be extracted for analysis. Research on protein precipitation is 
growing and many researchers have used protein precipitation in their analysis of drugs in 
serum and plasma (157).  
 
A study to determine the most competent protein precipitants for protein removal was 
undertaken and zinc sulphate (10%, w/v), acetonitrile and trichloroacetic acid (10%, w/v), 
were consistently found to remove plasma proteins effectively in all species at all precipitant 
to plasma volume ratios of 2:1 and greater (157). The chosen sample pre-treatment involved 
manual protein precipitation using acetonitrile with a ratio of sample: acetonitrile of 1:1.5, 
described by Polson et al. (157) followed by centrifugation to remove the precipitated 
proteins. Subsequently, evaporation is used to remove the supernatant solvents and the 
residue is then reconstituted in an appropriate solvent, in accordance with the analytical 
method used. Despite the fact that protein precipitation is neither as complex nor as time-
consuming as saponification, the disadvantage of protein precipitation is that the extract is not 
very clean and contains a considerable amount of impurities from the matrix. This finding 
may lead to poor selectivity and ion suppression in LC–MS (143). 
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1.10.2 Saponification 
Traditionally, the process of alkaline saponification for the extraction of vitamins and step-
wise HPLC analyses has been widely used for analysis of lipophilic vitamins in animal feeds 
and the most common procedure by which to extract vitamin D compounds from foodstuff 
(159). The hydrolysis reaction attacks ester bonds and releases the fatty acids from the 
glycerol of glycerides and phospholipids, as well as from esterified sterols and carotenoids 
(160). This reaction also frees vitamin D from any binding matrix that may exist.  
 
Given the lack of stability of vitamin D, it is common to use antioxidants such as pyrogallol 
(benzene-1,2,3-triol) (161), butylatedhydroxytoluene (2,6-di-tert-butyl-4-methylphenol) and 
ascorbic acid in the saponification process (162-166), combined with potassium hydroxide in 
ethanol or water solutions. The importance of potassium concentration in ethanol or methanol 
in saponification to obtain vitamin D in milk matrix has been reported in various studies. 
There was no significant difference when either methanol or ethanol were used (167). 
Ethanolic KOH prevents the formation of emulsions and mixes well with fat, but it requires 
daily preparation (168). In contrast, aqueous KOH does not mix so well with fat, but is more 
stable – this probably being the reason why it is more often used (168). With 1.9N KOH, D2 
and D3 recoveries are less than 40%; recovery doubles when increasing the KOH 
concentration to 3.8 N (167).  
 
Hot saponification consists of treating the sample with ethanolic or aqueous KOH at 
temperatures between 60–100 °C and times range of 20–45 min while cold saponification 
consists of treating the sample overnight with ethanolic or aqueous KOH at room 
temperature, under slow constant stirring (168). Thermal isomerisation of vitamin D to pre-
vitamin D may be avoided in a cold saponification procedure (isomerisation losses of less 
than 5% under cold conditions versus about 10–20% under hot conditions). Furthermore, this 
method provides satisfactory extraction and recovery and is simpler to operate with less 
operator attention (160, 169).  
 
Once saponification has been completed, the non-saponifiable fraction is extracted with 
organic solvents that are not miscible in water such as heptane, hexane, petroleum ether, di-
ethyl ether, pentane or mixtures of these substances. It is usually preferable to use hexane 
instead of di-ethyl ether since di-ethyl ether is more inflammable and unstable than hexane 
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and the latter can be simply removed at low pressure at a temperature below 50°C (160). 
However, Renken et al. preferred di-ethyl ether because it is less prone to form emulsions 
(170). In addition, there are various other conditional factors such as sample particle size 
(mesh), ratio of sample to reagent, extraction time, extraction equipment and pre-purification 
that can affect extraction efficiency (171). Subsequently, evaporation is used to remove the 
organic solvents and an appropriate solvent, according to the analytical method used, is used 
to reconstitute the residue. Nevertheless, the saponification procedure is time-consuming and, 
in addition, there is a considerable amount of complexity involved in the process.  
 
1.10.3 Liquid-liquid extraction (LLE) 
In vitamin D analysis liquid-liquid extraction (LLE), the sample is agitated in the presence of 
an extracting solvent that is not miscible with the sample (21, 172). Solvents such as hexane, 
heptane, ether, ethyl acetate, methyl t-butyl ether, dichloromethane, cyclohexane, isooctane, 
chloroform, pentane or mixtures of non-polar solvents have been frequently used (143). 
When the sample/solvent mixture has settled after agitation, and two layers of liquids are 
visible, organic layer will contain most of the vitamin D compound. The shaking action 
ensures that all parts of the sample come into contact with the extraction solvent. The organic 
layer is then removed, evaporated and the sample residue containing vitamin D compounds is 
reconstituted in a suitable solvent depending on the subsequent analytical technique to be 
used. LLE generally provides cleaner extracts than solid phase extraction (SPE) (173) and it 
is considered inexpensive and simple. However, it is not free of complications, for instance, 
the use of hazardous solvents, emulsion formation and low efficiency due to matrix effects in 
the sample, when compared with SPE (143). 
 
1.10.4 Solid phase extraction (SPE) 
Solid-phase extraction (SPE) has also been used for the extraction of vitamins from 
biological fluids (174-176). The SPE procedure consists of an initial conditioning of a 
reversed phase cartridge, application of the sample, subsequent washing followed by elution 
with a suitable solvent/solvent mixture. Several different SPE cartridges have been tested and 
different washing or elution solvents assessed in previous studies (175, 177, 178). After a 
sample application, metabolites are retained on the sorbent and subsequently washed to 
remove polar compounds. The sorbent is then eluted using a predominantly organic solvent to 
isolate the hydrophobic vitamin D compounds. Subsequently, the eluent is evaporated to 
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dryness and the extract concentrated by reconstituting the residue in a small volume of a 
suitable solvent, depending on the subsequent analytical method used. Some LC–MS 
methods using MS/MS detection for the quantification of vitamin D compounds in serum or 
plasma have employed on-line solid phase extraction after protein precipitation (78, 179). 
SPE systems have been developed for vitamin D metabolites including 25(OH)D3, 
25(OH)D2, 24,25(OH)2D3, 1,25(OH)2D3 and 1,25(OH)2D2 (177, 180, 181). 
 
Polar sorbents have been used in SPE clean-up processes of vitamin D compounds. For this 
class of sorbents, interactions between compounds and stationary phases may take place by 
hydrogen bonds, dipole-dipole, or π-π interactions (163, 165, 182-185). Some methods (186) 
have used immunosorbents but since vitamin D metabolites have similar chemical 
characteristics with other substances in biological fluids, cross reactivity may easily occur 
with immunosorbent SPE materials (143). 
 
SPE offers benefits such as lower sample volumes needed and less hazardous solvents used 
when compared to LLE extraction. In addition, there is no emulsion formation in SPE. 
However, SPE has some drawback; the most significant of which that, SPE is expensive 
because the SPE cartridges are intended for single use. Furthermore, the SPE clean-up 
procedure necessitates additional time and effort in method development. 
 
1.11 Derivatisation procedures 
Vitamin D metabolites are lipophilic in nature and have low abundance in human biological 
fluids; this makes the development of analytical assays very challenging. In addition, vitamin 
D metabolites have low ionisation efficiencies in electrospray (ESI) or atmospheric pressure 
chemical ionisation (APCI) sources because they lack easily charged groups, which would 
enhance ionisation efficiencies (187, 188). A common strategy is derivatisation to enhance 
the assay sensitivity of vitamin D metabolites in various human biological samples; 
derivatisation with 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD), a representative Cookson-
type reagent, has often been employed (187). In this reaction, the dienophile moiety of PTAD 
reacts with the s- cis- diene structure of 25(OH)D3 substances at carbon positions 19, 10, 6, 
and 5, resulting in the formation of a stable PTAD adduct (74, 153, 188, 189). Figure 1.7 has 
illustrated the formation of two epimers (6S and 6R) during derivatisation with PTAD, 
corresponding to the position of the dienophile relative to the plane of the A ring (153). 
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However, other derivatisation agents used such as Ampliflex® (23), custom-synthesized 
DAPTAD (4-(4'- dimethylaminophenyl)-1,2,4-triazoline-3,5-dione) (190) and 2-
nitrosopyridine (PyrNO) demonstrate that improved ionisation and higher sensitivity can be 
achieved compared to PTAD (191). 
Improvements in signal response have been achieved by the introduction of this reagent and 
some studies have reported previously that this process increases in sensitivity over non-
derivatised compounds (192-194). One study found that the optimum sensitivity increase for 
vitamin D-PTAD compounds was achieved when 100-fold molar excess of PTAD over 
vitamin D compounds was used with the reaction time of one hour (193, 195). Other 
advantages of derivatisation include the reduction of noise from low molecular impurities in 
the mobile phase thereby improving signal/noise ratio in the mass spectra by shifting to 
higher m/z range by derivatisation (195). Unfortunately, derivatisation procedures require 
time-consuming sample preparation steps thus less suitable for routine clinical application.  
 
 
Figure 1.7:Derivatisation of 25(OH)D3using 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD). 
PTAD reacts with the s-cis-diene structure of 25(OH)D3 substances at carbon positions 19, 
10, 6, and 5, resulting in the formation of two epimers (6S and 6R) . Adapted from (153) 
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1.12 Quantification 
It is common knowledge in analytical chemistry that the instrumental response can be 
affected by the sample matrix. With mass spectrometric detection in liquid chromatography, 
co-eluting impurities affect the analyte response due to ion suppression/enhancement. 
Compounds that are co-eluted with the analyte interfere with the ionization process in the MS 
detector, thereby causing ionisation suppression or enhancement (196). In mass spectrometry 
(MS), the ion suppression/enhancement effects due to the matrix can significantly reduce or 
enhance the analyte response thereby affecting sensitivity (197). Moreover, matrix effects 
encountered in LC-MS/MS techniques can affect accuracy, precision and the limit of 
detection (198). The matrix effect is one of the most relevant drawbacks when analysing 
human blood samples; the properties of vitamin D (such as its lipophilic nature and tight 
binding to vitamin D-binding protein (DBP)) have the potential to cause substantial matrix 
effects during sample extraction.  
 
An option can be suggested to minimise or to correct ion suppression/enhancement included: 
modifications of the MS conditions and carrying out an extensive sample clean- up to reduce 
matrix effects (199). If matrix suppression/enhancement phenomena cannot be eliminated or 
made negligible through the application of the strategies described, the only way to obtain 
accurate data is to remove the contribution from the interferences at the quantification step. 
The addition of stable isotope labelled-internal standard (SIL-IS) to the sample and 
subsequent quantification using internal standard (IS) calibration has become the most 
commonly used method to correct matrix effects in MS detection. Since the chemical 
properties and ionisation process of SIL-IS should be almost identical to those of the analyte, 
it will elute at the same retention time as the analyte and will experience the same extent of 
matrix effects (200). Although the magnitudes of the individual responses for the analyte and 
the internal standard will differ in the presence and absence of ion suppression/enhancement, 
the ratio of responses will be unaffected. Therefore, the use of stable isotope labelled internal 
standard (SIL-IS) for each vitamin D compound is essential to correct analytical errors 
caused by ion suppression effects and to ensure the accuracy and reliability of data (198, 201, 
202). Unfortunately, their use may be expensive, especially in a multicomponent analysis or 
may be impractical due to the lack of available commercial standards.  
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1.13  Conclusion 
This chapter has summarised the different forms of vitamin D and the possible risk factors of 
vitamin D deficiency in humans. Particular emphasis has been made on the analytical 
methods used for quantification and sample preparation procedures in a variety of matrices. 
Our knowledge regarding the consequences of vitamin D deficiency in humans is still 
incomplete and therefore requires further investigation. There is some evidence that the 
frequency of measurements of vitamin D in the human population has significantly increased 
over the last decade since vitamin D deficiency has now been linked to many diseases. This is 
due to each form of vitamin D having a different biological function, in addition to its 
established role in bone health. Serum 25(OH)D3 concentration is used to serve as a marker 
for vitamin D in plasma and serum. However, measuring 25(OH)D3 only provides an 
incomplete picture that may or may not correlate with function or disease. Vitamin D 
methods have been compared and critically evaluated at each stage of the quantification 
including extraction. This has enabled the evaluation of each stage of the analytical process 
and the selection or development of an appropriate method for a specific application.  
 
Liquid chromatography-mass spectrometry (LC-MS/MS) has emerged as the preferred 
analytical technique used for vitamin D assays, but immunoassays are widely employed in 
clinical settings.  These approaches are challenging, however, due to instrumental limitations 
with the detection of vitamin D compounds and the low concentrations of the metabolites in 
biological fluids. The development of new LC- MS/MS sources as well as improvements on 
derivatisation procedures are expected to address issues related to the poor ionisation 
efficiency in ESI or atmospheric pressure chemical ionisation of vitamin D compounds. 
Ideally, a desirable analytical method for vitamin D metabolites would cover all relevant 
high-and low-abundance species, using a universal and standardised analytical method (34).  
 
1.14  Research aim 
The aim of this research is to develop methods by which to measure quantitatively a wide 
range of vitamin D compounds, thereby creating a comprehensive picture of vitamin D status. 
A robust, efficient, reliable and inexpensive analytical method is to be developed to 
simultaneously measure 12 vitamin D compounds in human blood. Specific research 
objectives are as follows :- 
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1. To develop a sensitive, accurate and reliable LC-MS/MS method for the 
determination of 12 vitamin D compounds (D2, D3, 25(OH)D3, 25(OH)D2, 
1,25(OH)2D3, 1,25(OH)2D2, 24,25(OH)2D3, 24,25(OH)2D2, D3-S, D2-S, 25(OH)D3-S 
and 25(OH)D2-S). 
2. To compare the efficiencies of two different sample preparation methods (protein 
precipitation and saponification). 
3. To determine the appropriateness of the biological sample (serum and plasma) as the 
sample for vitamin D analysis and the sample size required to measure simultaneously 
12 vitamin D compounds in serum and plasma. 
4. To develop a method that is amenable for routine analysis. 
5. To apply the method to quantify the total vitamin D in other biological fluids. 
 
1.15  Research hypotheses 
1. Protein precipitation is a better sample preparation method to extract vitamin D from 
blood samples when compared to saponification followed by liquid-liquid extraction. 
2. There is no significant difference between plasma and serum as the optimum sample 
matrix for vitamin D assay analysis. 
3. LC-MS/MS approaches can simultaneously quantify the concentrations of 12 vitamin 
D compounds over wide concentration ranges. 
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CHAPTER 2: SIMULTANEOUS QUANTITATIVE ANALYSIS OF NINE VITAMIN 
D COMPOUNDS IN HUMAN BLOOD USING LIQUID CHROMATOGRAPHY-
TANDEM MASS SPECTROMETRY (LC- MS/MS) 
___________________________________________________________________________ 
2.1 Foreword 
This chapter describes the attempts to develop and validate an LC-MS/MS method for the 
sensitive and accurate quantification of 12 vitamin D compounds in human blood. A 
comparative evaluation of sample type and extraction method were carried out. Based on this 
comparison, a sensitive LC-MS/MS method was developed and validated. Much work of this 
chapter has been published in the journal Bioanalysis, 2016; 8:397–411; doi: 
10.4155/bio.15.260. However, to be compatible with the style and the flow of the thesis, 
some modifications have been introduced. The references have been revised to follow the 
format used in the thesis, as well as the numbering for Tables and Sections. Sections have 
been added at the end of the chapter to include additional work that has been undertaken for 
this chapter but has not been published. 
 
2.2 Introduction 
Historically, numerous studies have been undertaken concerning the role of vitamin D in 
bone health. Recent studies have, however, concentrated more on elucidating the ways in 
which the vitamin and its metabolites may influence other pathologies (11, 35). In addition to 
the well-known effect of vitamin D’s role in bone formation, there is now growing evidence 
that vitamin D deficiency can increase the risk of other major diseases such as cancer, 
cardiovascular diseases, schizophrenia and depression (5). These findings have led to a 
significant increase in studies investigating links between vitamin D levels and such 
conditions. 
 
Although vitamin D has more than 50 metabolites, only two metabolites, namely, 25-
hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D], have been 
afforded the greatest clinical attention in relation to their quantification (35, 203). 
Controversy, however, remains regarding the forms of vitamin D and their function; a 
comprehensive, sensitive and robust assay methodology for vitamin D metabolites is 
therefore required (48). Vitamin D2 (D2 or ergocalciferol) and vitamin D3 (D3 or 
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cholecalciferol), the major forms in ingested food, are considered to be biologically inactive 
(11) and they are metabolised in the liver to 25(OH)D2 (25-hydroxyvitamin D2) and 
25(OH)D3 (25-hydroxyvitamin D3), collectively referred to as 25(OH)D. Subsequently, they 
are hydroxylated to 1,25(OH)2D(collectively referred to as1,25-dihydroxyvitamin D2 and 
1,25-dihydroxyvitamin D3) or 24,25(OH)2D (collectively referred to as 24R,25-
dihydroxyvitamin D2 and 24R,25-dihydroxyvitamin D3).  
 
Of the four known sulfated conjugates, vitamin D-sulfate (D3-S and D2-S) and 25-
hydroxyvitamin D-sulfate (25(OH)D3-S and 25(OH)D2-S), 25(OH)D3-S has been the only 
form found in human and animal blood to date (77). The circulating levels of this compound 
were found to be similar to or higher than those of 25(OH)D3 in adults and infants, 
respectively (19, 77, 80). Since the level of 25(OH)D3S is similar to or exceeds that of the 
major circulating form of vitamin D in adults, it was viewed as being important in 
researching the significance of the sulfate metabolite in pregnant women and newborns (80). 
Despite being a major circulating form of vitamin D in man the biological role of 25(OH)D3-
S is not yet known, and has been therefore, considered to be a “storage” form of the major 
circulating form 25(OH)D3 (77). The lack of research into the biological function of 
25(OH)D3-S may be due to the scarcity of the methods available for its accurate 
quantification, until recently, for its accurate quantification (78). In studies where up to six 
analogues and two epimers of vitamin D were determined simultaneously, sulfate metabolites 
were not included (204).  
 
Considering the above information, and, given the differences in biological activities of each 
vitamin D form, it is important to selectively and accurately quantify each form of vitamin D 
separately. It is also timely to develop an assay that can simultaneously determine as many 
forms of vitamin D as possible, including the most active forms. An ideal analytical method 
would cover all ranges of concentration for all vitamin D metabolites with one standardised 
analytical method (34). We present here the development of a method that is capable of 
accurately and selectively quantifying nine compounds of vitamin D as well as capable of 
separating the epimeric compounds of the major circulating form 25(OH)D3, in human blood. 
This method will facilitate clinical research into the study of the biological function/s of each 
form and their potential roles in a variety of clinical conditions. 
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The majority of the studies on vitamin D have used serum as it is recognised that serum 
25(OH)D3 concentration measurements provide the single best assessment of vitamin D 
status (203). In contrast, some studies have reported that the levels of 25(OH)D3 in plasma 
represent the best indicator of physiological vitamin status. A recent study using a solid phase 
extraction (SPE)-LC/MS method, confirmed that vitamin D3, 24,25-dihydroxyvitamin D3 and 
25-hydroxyvitamin D2 levels in plasma and serum were similar, while levels of 1,25-
dihydroxyvitamin D3 were significantly different, being higher in plasma than in serum (142). 
 
As the potency of 25(OH)D2 is considered to be less than one third of the potency of 
25(OH)D3 (43), the most common method used to measure vitamin D, immunoassay-based 
methods, due to their inability to differentiate between these compounds, may overestimate 
the in vivo vitamin D status. Furthermore, some immunoassay methods are known to not 
detect 25(OH)D2 with adequate sensitivity therefore adding more potential inaccuracy to the 
measured vitamin D status (48). The application of liquid chromatography-tandem mass 
spectrometry, with its associated high selectivity and sensitivity, has been used increasingly 
in vitamin D assay methods in recent years (143) and it has greatly facilitated the 
determination of individual compounds of vitamin D. In terms of quantifying a variety of 
forms, the most significant study so far has been one that was developed for the 
quantification of six forms of vitamin D, with two epimers separated (204).  
 
Mass spectrometry (MS) detection is susceptible to matrix effects, in the form of ionisation 
suppression or enhancement that can detrimentally affect both accuracy as well as sensitivity. 
Complete chromatographic separation of all interfering matrix compounds from all analytes 
of interest in every sample is likely unachievable. Therefore, correction for matrix effects 
using co-eluting (stable isotope labelled) analogues as internal standards for each analyte is 
the optimal way to ensure the accuracy and reliability of data (201). In this study, we 
employed an internal standard calibration method using stable isotope labelled analogue for 
each of the 12 compounds of vitamin D. 
 
Vitamin D metabolites have low ionisation efficiencies in electrospray (ESI) or atmospheric 
pressure chemical ionisation (APCI) sources due to the lack of charged groups that would 
help to enhance ionisation efficiencies. The conjugated diene group of vitamin D metabolites, 
however, renders them a specific target for Diels–Alder derivatisation. The derivatisation 
reagents present polar groups and accordingly normally bring about a 100–1000-fold increase 
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in sensitivity over non-derivatised compounds, depending on the vitamin D compound (188). 
In this study, we applied the commonly used 4-phenyl-1,2,4- triazoline-3,5-dione (PTAD) 
(205) to derivatise the vitamin D compounds prior to LC-MS/MS analysis. 
Traditionally, a saponification method with subsequent extraction has been used for the 
determination of vitamin D from foodstuffs including milk, and protein precipitation has been 
used in plasma and serum analysis. There have been only a limited number of instances 
where saponification has been used for serum and plasma (143) and, to date, there have been 
no studies that have compared these two major methods of sample preparation. Therefore, in 
the following report, saponification and protein precipitation were compared for their 
effectiveness in extracting vitamin D from human blood samples from volunteer adults. 
 
2.3 Materials and methods 
2.3.1 Serum and plasma samples 
Blood samples were obtained from volunteer staff and research students of the School of 
Pharmacy, University of Queensland. Ethical approval was obtained from the Institutional 
Human Research Department, The University of Queensland. Participants’ blood samples 
were taken by the pathology laboratory in the UQ Health Care Centre. The sample size was 
10 mL Blood was collected in Vacutainer tubes containing either EDTA or without 
anticoagulant, for plasma and serum samples, respectively. 
 
2.3.1.1 Serum preparation 
Blood samples were collected in yellow-topped evacuated tubes from Becton Dickinson (BD) 
with no anticoagulant. BD’s trade name for the blood handling tubes is Vacutainer. The 
sample was incubated in an upright position at room temperature for 30-45 min (not longer 
than 60 min). The clot was removed by centrifugation at 1000-2000 x g for 15 min at room 
temperature. The resulting supernatant was designated serum. The samples were maintained 
at 2-8 °C while handling. The supernatant (serum) was apportioned into 500 µL aliquots in 
Eppendorf tubes and stored at -80 °C. It is important to avoid freeze-thaw cycles because this 
can be detrimental to many serum components. Samples were labelled with the relevant 
information. 
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2.3.1.2 Plasma Preparation 
Blood samples were collected into anticoagulant with EDTA treated tubes (lavender tops). 
Cells were separated from plasma by centrifugation for 15 min at 1000 - 2000 x g using a 
centrifuge at room temperature. The resulting supernatant is designated plasma. The samples 
were maintained at 2-8 °C while handling. Plasma was apportioned into 500 µL aliquots in 
Eppendorf tubes and stored at -80 °C. It is important to avoid freeze-thaw cycles because this 
can be detrimental to many plasma components. Samples were labelled with the relevant 
information. 
 
2.3.2 Chemicals and reagents 
All reagents and solvents were of analytical grade or LC- MS grade. PTAD (≥97%) was 
purchased from Sigma Aldrich (St. Louis, USA). Acetonitrile, ascorbic acid, 
dichloromethane, ethanol, hexane, methanol and potassium hydroxide were purchased from 
Merck (Darmstadt, Germany). Formic acid (>99%) was purchased from Fisher Chemical 
(Geel, Belgium). High-purity water was prepared in-house using a Millipore Milli-Q system 
(Milford, USA). Water and solvents used for the mobile phases were filtered with a 0.2-μm 
Supelco Nylon 66 membrane (Supelco, Bellefonte, PA, USA). 
 
Standard vitamin D compounds and several of their stable isotope labelled analogues [D2, D3, 
D2-S, D3-S, 25(OH)D2, 25(OH)D3, 25(OH)D2-S, 25(OH)D3-S, 24,25(OH)2D2, 24,25(OH)2D3, 
1,25(OH)2D2, 1,25(OH)2D3, D2-d3, D3-d3, D2-S-d3, D3-S-d3, 25(OH)D2-S-d3, 25(OH)D3-S-d3, 
24,25(OH)2D2-d6, 24,25(OH)2D3-d3, and 1,25(OH)2D3-d6] were purchased from IsoScience 
(King of Prussia, USA). Other labelled analogues (25(OH)D2-d6 and 25(OH)D3-d6) were 
purchased from Chemaphor (Ottawa, Canada), (1,25(OH)2D2-d6)Medical Isotopes Inc. 
(Pelham, USA), and (24,25(OH)2D2-d6) Toronto Research Chemicals Inc. (Ontario, Canada). 
All compounds had a purity of 97% or better. 
 
2.3.3 Preparation of standards and sample solutions 
All preparations were performed under subdued light. Stock solutions in ethanol of all 
standard compounds were prepared at a concentration of 1µM, were sub-divided into small 
volumes, and stored in amber Eppendorf tubes at -20°C. All working solutions were prepared 
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by serial dilution of stock solutions. Several aliquots (500 µL) of plasma and serum were 
accurately measured and frozen at -80°C until analysis. 
 
2.3.4 Optimisation of saponification followed by liquid-liquid extraction method 
Plasma (250 µL) was mixed with 250 µL of two different concentrations (4M or 8M) of 
potassium hydroxide in ethanol containing 20% ascorbic acid. The saponification reaction 
was carried out for 20 min at 80°C, 3 h at room temperature or overnight (12 h) at room 
temperature. This 2x3 variable factorial design was carried out with triplicate samples for 
each treatment combination, totalling 18 samples. After completion of saponification, the 
mixture was centrifuged at 4000 xg for 10 min. The supernatant was transferred to a clean 
Eppendorf tube, and 675µL hexane: dichloromethane mixture (4:1, v/v) was added. The 
solution was then vortex mixed for 1 min. The upper clear layer was transferred to a new tube 
and dried under a gentle stream of nitrogen at room temperature. The dry residue was 
subjected to derivatisation with PTAD, as described below. The derivatised mixture was 
evaporated to complete dryness under a gentle stream of nitrogen and the residue 
reconstituted with 50 µL mobile phase (77 %B – see below) prior to LC-MS/MS analysis. 
Peak areas were used to assess the efficiency of each set of conditions.  
 
2.4 Optimisation of sample preparation 
2.4.1 Protein Precipitation 
Plasma/serum (500 µL) was mixed with 1000µLof acetonitrile and 25 µL of the combined 
internal standard solution (to give the same concentrations as those in calibration standards in 
the final solution injected onto LC-MS/MS), then vortex mixed for 1 min. The mixture was 
incubated for 15 min at room temperature to allow protein precipitation to be completed and 
was then centrifuged at 4000 x g for 10 min. The supernatant was transferred to a clean 
Eppendorf tube and evaporated under a gentle stream of nitrogen gas at room temperature to 
evaporate most of the acetonitrile. The remaining solution in each tube was then frozen at -
80°C for one hour, then evaporated using a freeze drier operated at -80°C (12 h). The dry 
residue was subjected to a derivatisation reaction with PTAD, as described below.  
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2.4.2 Saponification 
The procedure used was similar to that in 2.3.4 using the optimised conditions: 8M potassium 
hydroxide in ethanol (500 µL) containing 20% (w/v) ascorbic acid added to plasma/serum 
(500 µL) and overnight (12 h) saponification at room temperature. The combined internal 
standard solution (25 µL; to provide the same concentrations as those in calibration standards 
in the final solution injected to LC-MS/MS) was added to plasma/serum before adding the 
saponification mixture. 
 
2.5 Derivatisation reaction 
The dried residue obtained from protein precipitation or saponification was vortex mixed 
with 350 µL of derivatising agent, PTAD (10 mM in ACN), for 1 min. The mixture was 
incubated at the room temperature for 1 hr, then, upon completion of the reaction, the excess 
PTAD was reacted with ethanol (50 µL). The solvent was evaporated to complete dryness 
under a gentle stream of nitrogen at room temperature. The dry residue was reconstituted 
with mobile phase (50 µL; 77%B –section 2.6), and centrifuged before transferring the 
supernatant into HPLC vials. An aliquot (20µL) was injected into the LC-MS/MS system for 
analysis. For standards, the mixed standard solution at appropriate concentrations was 
evaporated under a gentle stream of nitrogen gas to dryness, then derivatised with PTAD and 
reconstituted with mobile phase as described above. 
 
2.6 LC-MS/MS procedure 
An Agilent binary LC system consisting of an Agilent 1290 infinity LC pump, Agilent 1290 
well plate auto-sampler and a Poroshell 120 EC-C18 (150 x 2.1 mm, 2.7 μm) column (Agilent 
Technologies, Santa Clara, CA, USA) was used for separations. A binary solvent consisting 
of 0.1% formic acid in water (A) and 0.1% of formic acid in methanol (B) was used for 
separation. Isocratic elution was maintained for 12.5 min at 77%B. The composition of the 
mobile phase was then changed from 77% B to 100% B over the next 1.5 min. Thereafter, it 
remained at 100% B over the next 9 min. The mobile phase was then returned to the starting 
composition of 77% B over the next 1 min, and the column was subsequently re-equilibrated 
with 77%B for 10 min before injecting the next sample. The total run time including the 
equilibration of the column was 34 min. The mobile phase flow rate was 0.2 mL/min and the 
injection volume was 20 μL. 
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An Agilent 6460 triple quadrupole tandem mass spectrometer equipped with a Jet Stream 
source and supported by Mass Hunter Workstation software (Agilent Technologies, Santa 
Clara, CA, USA) was used as the detector, in ESI positive mode. For all compounds, the MS 
parameters were optimised to obtain the highest signal in MRM mode. Table 2.1 shows the 
optimised parameters and the MRM and qualifier ions used. Source parameters including gas 
flow, sheath gas flow, gas temperature and sheath gas temperature were optimised and 
maintained at 5 and 12 L/min (gas and sheath gas flows, respectively) and at 300oC and 
250oC (gas and sheath gas temperatures, respectively). The capillary and nozzle voltages 
were, respectively, maintained at 5000V and 2000V. 
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Table 2.1: Optimised mass spectrometry parameters used in MS detection 
 
Vitamin D compounds 
with PTAD 
 
MRM pair  
Precursor ion - 
Product ion  
Qualifier 
ion  
Fragmentor 
Collision 
energy  
(m/z) (m/z) (V) (V) 
D3-PTAD  560-298 161 96 12 
D3-d3-PTAD  563-301 - 96 12 
D2-PTAD  572-298 161 96 16 
D2-d3-PTAD  575-301 - 96 16 
25(OH)D3-PTAD 558-298 161 168 12 
25(OH)D3-d6-PTAD  564-304 - 168 12 
25(OH)D2-PTAD  570-298 161 144 12 
25(OH)D2-d6-PTAD  576-304 - 144 12 
25(OH)D3-S-PTAD  639-378 161 144 12 
25(OH)D3-S-d3-PTAD  642-381 - 144 12 
25(OH)D2-S-PTAD  650-378 161 144 12 
25(OH)D2-S-d3-PTAD  653-381 - 144 12 
1,25(OH)2D3-PTAD 574-314 177 139 8 
1,25(OH)2D3-d6-PTAD  580-320 - 139 8 
D3-S-PTAD  640-378 161 124 12 
D3-S-d3-PTAD 643-381 - 124 12 
1,25(OH)2D2-PTAD  586-314 135 144 12 
1,25(OH)2D2-d6 -PTAD  592-320 - 144 12 
D2-S-PTAD  652-378 161 134 16 
D2-S-d3-PTAD  655-381 - 134 16 
24,25(OH)2D3-PTAD  574-298 161 198 20 
24,25(OH)2D3-d3-PTAD  577-301 - 198 20 
24,25(OH)2D2-PTAD  586-298 161 178 12 
24,25(OH)2D2-d6-PTAD  592-304 - 178 12 
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2.7 Method Validation 
The calibration standards (six levels) were prepared in mobile phase (77%B) to cover the 
following concentration ranges of the derivatised compounds: 50-1250 nM (25(OH)D3, 
25(OH)D2, D2, D3, and 25(OH)D3-S); 5-100 nM (25(OH)D2-S); 0.1-2 nM (1,25(OH)2D3and 
D3-S); 0.05-0.4 nM (1,25(OH)2D2and D2-S); 10-100 nM (24,25(OH)2D3) and 1-10 nM 
(24,25(OH)2D2). The (derivatised) internal standard concentrations in all calibration 
standards were: 500 nM (25(OH)D3-d6, 25(OH)D2-d6, D2-d3, D3-d3, and 25(OH)D3-S-d3); 50 
nM (25(OH)D2-S-d3 and 24,25(OH)2D3-d6); 1nM (1,25(OH)2D3-d3, and D3-S-d3); 0.1 nM 
(1,25(OH)2D2-d6, and D2-S-d3) and 5 nM (24,25(OH)2D2-d3). Linearity was assessed by 
plotting the peak area ratios of standard: internal standard against the concentration of the 
standards using linear regression analysis.  
 
The on-column limit of detection (LOD) was estimated as 3 x noise and limit of quantitation 
(LOQ) as 10 x noise for each compound. Repeatability was determined by analysing 10 
separate aliquots of pooled serum sample followed by the calculation of the percentage 
relative standard deviation for each vitamin compound. Recovery was assessed by analysing 
the concentration of each vitamin D analogue in six separate aliquots of spiked and un-spiked 
serum samples. Each aliquot of serum was spiked to give an added concentration similar to 
the second level of the calibration range used in this study. 
 
2.8 Results and discussion 
2.8.1 LC-MS/MS method development for vitamin D compounds and epi-25(OH)D3 
The quantification of different vitamin D forms has been a recent trend (143) driven partly by 
the necessity to study the biological function of each form (48) and partly due to the 
availability of LC-MS/MS technology that possesses the necessary selectivity and sensitivity. 
The best method available to-date, in terms of the number of forms analysed, was able to 
quantify six vitamin D compounds (204). The two principal problems with vitamin D assays 
using LC- MS/MS have been the lack of sensitivity in MS detection (due to the lack of 
ionisable groups in vitamin D molecules) (153) and the accuracy/reliability concerns due to 
ion-suppression effects caused by endogenous interfering compounds in complex matrices 
such as plasma and serum. In this study, we overcame the sensitivity problem by 
derivatisation with PTAD to enhance ionisation. The inaccuracies introduced due to ion 
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suppression effects were corrected by using co-eluting labelled analogues of each vitamin D 
compound in internal standard calibration. 
 
Each derivatised vitamin D compound was individually subjected to MS parameter 
optimisation. For this experiment, only a small excess (5X) of PTAD was used because the 
suppression resulting from a large excess of PTAD (as used in the developed LC-MS/MS 
method) produced very small or non-existent MS signals, when directly infused into MS. The 
optimized MS parameters are shown in Table 2.1. The internal standard of each form was 
detected using the same parameters, so that both compounds experience the same conditions. 
To further ensure that the internal standard and the corresponding unlabelled compound were 
analysed using the same conditions thus enabling correction of ion suppression effects, 
chromatograms were checked for compound co-elution. 
 
Chromatography was optimised so that the first peak of interest was satisfactorily remote 
from early eluting interfering compounds, including the excess PTAD reagent. This 
minimised the potential ion suppression effects on vitamin D compounds of such early 
eluting compounds. Another aim of chromatographic optimisation was the separation of the 
epimeric form from 25(OH)D3. The use of methanol, when compared to acetonitrile, 
provided improved selectivity, enabling the separation of epimeric forms. Chromatograms 
obtained for a standard mixture, using the optimum LC and MS conditions are shown in 
Figure 2.1. Seven of the vitamin D-PTAD compounds (including the epimeric form of 
25(OH)D3) were chromatographically resolved, and D2 and D3 pairs of other forms co-elute. 
This co-elution poses no problems on method accuracy or selectivity because these forms are 
mass spectrometrically well separated, based on their MRM transition pairs, and because the 
use of co-eluting internal standards for each form correct the ion suppression effects from 
each other. PTAD derivatisation produces two isomers (R and S) for each vitamin compound, 
but they are not always separated, as has been observed in previous methods (188, 194, 206). 
The quantification reported here is based on the total peak area of the R and S forms, 
therefore the resolution of these two isomeric forms is unimportant.  
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Figure 2.1: LC-MS/MS profiles of 13 vitamin D compounds in the standard mixture 
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2.8.2 Optimisation of the saponification method 
Two approaches (protein precipitation and saponification with extraction) have been used 
previously to extract vitamin D from blood. However, the use of saponification has been 
limited (143). In our study, one of the aims was to extract the maximum amount of vitamin D 
from the matrix. To achieve this, we compared the two methods for their effectiveness in 
terms of amounts of each vitamin D compound extracted. Although protein precipitation is 
well established for use with blood samples, saponification is not. We considered that it was 
important to optimise the saponification method for blood samples prior to its application to a 
comparison study. 
 
Saponification uses alkaline hydrolysis to break the ester linkages of triglycerides, 
phospholipids and esterified sterols, thereby releasing the vitamin compounds (207). 
Saponification procedures have been reported with the use of potassium hydroxide in ethanol 
or water solutions, containing ascorbic acid as the antioxidant as an alternative to reduce the 
instability of vitamin D compounds (168). The amount of vitamin D released may be 
dependent on the concentration of potassium hydroxide used in the saponification reaction 
and on the time/temperature of the reaction. The concentrations used for extraction of vitamin 
D compounds from milk (a food matrix somewhat similar to blood) varied from 4-8 M (167) 
and the temperature and time varied from room temperature to 80°C and 3 h to overnight (12 
h) (155, 208). As described in the experimental section, we used a 2x3 factorial design to 
optimise the plasma saponification methodology. The results for the two major forms of the 
vitamin are shown in Figure 2.2. The saponification mixture containing 8M ethanolic 
potassium hydroxide and reacted for 12 h at room temperature extracted the greatest amounts 
of all major vitamin D forms. Higher concentrations of KOH and extended reaction times 
release more vitamin. Although a higher temperature could have generally reduced the 
reaction time, in this case it did not; vitamin D is known to undergo thermal isomerisation to 
pre-vitamin D at high temperatures. It was reported that less than 5% isomerisation occurs 
under cold conditions compared to 10 - 20% at 60°C (168).  
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Figure 2.2:Signal responses for major vitamin D compounds using a range of saponification 
conditions (error bars represent ±1SD, n = 3) 
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2.8.3 Comparison of sample types used for the vitamin D assay 
The major difference between plasma and serum is the removal of fibrinogen and associated 
proteins by the coagulation process (138). The absence of the anticoagulant in the serum 
preparation permits an increase in the concentration of organic solvent used and these 
conditions then enhance the protein precipitation process (142). There is limited evidence that 
different collecting procedures and the presence or absence of the coagulation cascade 
influence the concentrations of both proteins and vitamin D compounds in these matrices. 
One concern, however, was the effect of anticoagulants on LC- MS/MS assay performance 
(141). This study demonstrated that different sample matrices, serum, heparin or K2-EDTA 
coagulated plasma, did not cause significant variation in 25(OH)D2 and 25(OH)D3 
quantification (141). In order to do a systematic comparison study, we used pooled samples 
of human serum and plasma from several healthy adults. As the comparison of the two 
methods (protein precipitation and saponification with extraction) was not done at this stage, 
both methods were used for each sample type. The saponification method used was the one 
reported above. Concentrations of each vitamin D compound were determined using the 
internal standard calibration method. Results shown in Figure 2.3 are expressed in vitamin D 
concentrations in serum or plasma; protein precipitation released higher concentrations for 
nine forms of vitamin D. For all vitamin D compounds, serum produced higher concentration 
levels of vitamin D. Based on these results, serum was selected as the sample type for the 
remainder of this study. 
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Figure 2.3: Comparison between serum and plasma using protein precipitation and 
saponification procedures for the extraction of nine vitamin D compounds. Error bars 
represent ±2SD (n=3). PP, Protein precipitation; SN, Saponification 
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2.8.4 Comparison of methods used for vitamin D assay 
To our knowledge, the two sample preparation methods (protein precipitation and 
saponification) have not been compared for their performance in vitamin D assay methods in 
serum. Serum samples from 10 individuals were used for this comparison. In our preliminary 
study, protein precipitation extracted significantly higher amounts of vitamin D when 
compared to saponification, as shown in Figure 2.4; significant losses of vitamins during 
saponification have been previously reported (143). Based on the results obtained, further 
work was undertaken using the protein precipitation method to extract vitamin D from serum. 
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Figure 2.4: Comparison between protein precipitation and saponification procedures using 
serum. Mean concentrations of forms in 10 individuals shown. Error bars represent ± 1SD 
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2.9 Method validation and application to samples 
The LC-MS/MS method developed in 2.6 was combined with the optimal sample type and 
extraction method, as established in 2.8.3 and 2.8.4, to obtain the optimum assay method for 
all the forms of vitamin D chosen in this study. This method was then validated, as described 
in the experimental section. The calibration ranges used for each form of vitamin D were 
based, where available, on levels reported previously (78, 204, 206, 209, 210). In our study, 
the calibration standards were prepared in the mobile phase solvent at the same composition 
as the initial gradient conditions as described in LC-MS/MS section 2.7. Previous work has 
established that, when isotopically labelled standards are used as internal standards, there is 
no significant difference in the results when the calibration standard are prepared either in 
mobile phase solvent or in matrix matched medium (211, 212). Therefore, matrix matching of 
samples and those of calibration standards was not required since a co-eluting stable isotope 
labelled internal standard was used for each analyte quantified. This approach represents a 
significant time advantage and is additional to the role of the internal standards in improving 
precision and accuracy, as described earlier. For those compounds where the levels were not 
available, the lowest concentration ranges used for other vitamin D forms were used. Table 
2.2 shows the results of regression analysis of the internal standard calibration (peak area 
ratio of standard/internal standard plotted against concentration of standard). The results 
show good linearity (R2> 0.99) for all 12 vitamin D compounds within the concentration 
ranges of interest. Table 2.2 also shows the on-column LOD and LOQ values in fmol, 
estimated as described in the experimental section, and the same in terms of concentrations in 
serum in pM (in parenthesis), calculated based on volume of injection of 20 µL, and taking 
into account dilution effects. 
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Table 2.2:Linearity, limit of detection (LOD), limit of quantification (LOQ), repeatability and recovery of all vitamin D 
 
      Repeatibility (n=10) 
Recovery 
(n=6) LOD (LOQ) * LOD (LOQ) ** LOD (LOQ) *** 
Vitamin D 
compounds 
with PTAD 
Linearity equation R2 
Mean ± SD 
(nmol/L) 
RSD 
(%) 
Mean (%) ± 
SD (nmol/L) 
pM pM femtomols 
D3 y = 0.0008x + 0.4025 0.995 12.657 ± 0.0112 0.09 98.5 ± 5.02 14 (47) 1.4 (4.7) 0.28 (0.94) 
D2 y = 0.0005x + 0.0283 0.996 5.879  ± 0.0546 0.93 100.6 ± 4.13 14 (47) 1.4 (4.7) 0.28 (0.94) 
25(OH)D3 y = 0.0042x + 0.0824 0.997 30.733 ± 0.7068 2.3 98.56 ± 2.37 19 (50) 1.8 (5.0) 0.38 (1.00) 
25(OH)D2 y = 0.0023x - 0.0547 0.995 15.016 ± 0.3555 2.37 100.6 ± 7.62 11 (38) 1.1 (3.8) 0.20 (0.76) 
25(OH)D3-S  y = 0.001x - 0.0256 0.997 4.168 ± 0.0902 2.2 96.2 ± 0.01 30 (100) 3.0 (10) 0.60 (2.00) 
25(OH)D2-S y = 0.0115x + 0.0214 0.998 - - - 43 (143) 4.3 (41.3) 0.86 (2.86) 
1,25(OH)2D3 y = 0.4489x + 0.1198 0.995 0.245 ± 0.0030 1.23 98.9 ± 0.09 10 (33) 1.0 (3.3) 0.20 (0.66) 
D3-S y = 0.5533x - 0.0377 0.991 - - - 28 (130) 2.8 (13.0) 0.56 (2.60) 
1,25(OH)2D2 y = 1.9038x - 0.0061 0.992 0.051 ± 0.0020 3.71 98.7 ± 7.46 10 (36) 1.0 (3.6) 0.20 (0.72) 
D2-S y = 2.3457x + 0.1205 0.992 - - - 37 (126) 3.7 (12.6) 0.74 (2.50) 
24,25(OH)2D3 y = 1.7725x - 0.7883 0.995 16.680 ± 0.1409 0.84 96.4 ± 0.38 18 (45) 1.8 (4.5) 0.36 (0.90) 
24,25(OH)2D2 y = 0.0718x - 0.0331 0.992 1.477 ± 0.0023 0.16 95.1 ± 2.74 20 (43) 2.0 (4.3) 0.40 (0.86) 
* Concentration in extract 
** Concentration in serum 
*** On column amounts
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The repeatability values (n = 10), determined by analysing multiple aliquots of a pooled 
human serum sample, and expressed as percentage standard deviations, are shown in Table 
2.2. The method is precise with percentage standard deviations within the range 0.09% to 
3.71%. The accuracy of the method, determined as the mean recoveries ranged from 95% to 
101% as also shown in Table 2.2.Three of the compounds were not recovered therefore 
failed the validation. Table 2.3 shows the ranges of vitamin D (nine compounds for which the 
method was validated) detected in 10 healthy adult serum samples using the optimised 
validated method. It is worth emphasising that although the number of samples is small, a 
trend was observed of higher levels of D2 and its metabolites being detected in the serum 
from two volunteers who had been taking vitamin D2 supplements (2400IU/day). The lowest 
levels of vitamin D were detected in those volunteers who were not receiving vitamin D 
supplements.  
 
Table 2.3:Concentrations ranges of vitamin D compounds in serum from 10 volunteers 
 
Vitamin D compounds with PTAD Concentration ranges (nmol/L) 
D3 3.04-36.2 
D2 0.863-6.46 
25(OH)D3 19.2-104 
25(OH)D2 16.4-52. 2 
25(OH)D3-S  6.81-20.1 
1,25(OH)2D3 0.148-0.347 
1,25(OH)2D2 *0.000 -0.020 
24,25(OH)2D3 1.03-2.71 
24,25(OH)2D2 0.508-2.29 
*Concentration below limit of detection for two samples
Chromatographic profiles of a typical serum sample showing all detected vitamin D forms 
are shown in Figure 2.5. As evident from Table 2.2 and Figure 2.5, only nine out of twelve 
compounds were detected in serum. This was not only due to the presence of very low levels 
in serum but also because the extraction method and/or LC-MS/MS method were not ideal 
for the three vitamin D forms D2-S, D3-S and 25(OH)D2-S. This conclusion was based on the 
observations that the spiked levels for these three were not recovered, and that the added 
internal standard compounds of these analytes were also not detected. Further work is 
necessary to explain these observations. 
 52 
 
  
 53 
 
 
Figure 2.5:Chromatographic profiles showing all detectable vitamin D compounds in human 
serum samples 
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2.10 Conclusion 
Although it has been suggested that each member of the family of vitamin D compounds may 
have different function/s, the specific functions and their relation to human health have not 
been well explored. The lack of selective quantification methods for each vitamin D 
compounds may have been a significant contributing factor for the scarcity of clinical 
research on individual vitamin D compounds. With the expansion of the scope of vitamin D 
assay methods, such as the method described here, more clinical research will be focused on 
the role of each vitamin D compound on human health. In time, the roles of D group vitamins 
will be well established, similar to those of the B group vitamins. 
 
  
 55 
 
Additional section 
2.11 Optimisation of sample volume and number of liquid-liquid extractions (LLE) 
2.11.1 Introduction 
In this study, a determination of the minimum sample size required to measure 
simultaneously all major vitamin D compounds in blood was performed. The number of 
extractions necessary for liquid-liquid extraction was adjusted to obtain the optimal recovery 
of vitamin D compounds prior to analysing serum samples using LC-MS/MS. We used a 2 x 
2 factorial design to optimise the sample volume and the number of extractions using the 
protein precipitation method. 
 
2.11.2 Preparation of samples 
Serum (250 µL or 500 µL) was mixed with acetonitrile (500 µL or 1000 µL) respectively, 
then vortex mixed for 1 min. The mixture was incubated for 15 min at room temperature to 
allow protein precipitation to proceed to completion. The mixture was then centrifuged at 
4000 xg for 10 min and the supernatant was transferred to a clean Eppendorf tube. The 
remaining solution was extracted with hexane: dichloromethane (4:1, v/v) and the solution 
was then vortex mixed for 1 min. Samples (250 µL or 500 µL) were either one time or three 
times extracted with 500 µL or 1500 µL of hexane: dichloromethane (4:1, v/v), respectively. 
Each of the upper clear layers of supernatant was collected and transferred to a clean set of 
tubes and dried under a gentle stream of nitrogen gas at room temperature and subjected to 
further derivatisation reaction with PTAD, and analysed as described in sections 2.5 and 2.6 
as above. Peak areas were used to assess the efficiency of each set of conditions.  
 
2.11.3 Results and discussion 
Initially, different ratios of hexane-dichloromethane for liquid-liquid extraction (LLE) were 
evaluated in our laboratory (195). Optimum results were obtained with hexane-
dichloromethane (4:1, v/v) ratio especially for the metabolites that are relatively more polar 
(195). Thus, further extractions were conducted using the optimised LLE ratio in this study. 
Pooled samples of human serum from volunteers were used. The recoveries with 250 µL and 
500 µL sample size were determined by using the similar numbers of extraction (three times) 
compared to one time extraction. The use of a higher volume of extraction solvent by 
increasing the number of extractions was shown to release higher concentration for seven 
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vitamin D compounds. While using the similar numbers of extraction, the recoveries with 
500 µL and 250 µL sample size were determined. The greater the volume of the sample used 
in analysis, two-fold vitamin D compounds were identified. For 1,25(OH)2D3 and 
1,25(OH)2D2 metabolites, since the level of these compounds in blood in extremely low 
(picomolar) level, a larger sample is required for quantification: both compounds were not 
detectable when using a 250 µL sample size. Figure 2.6 demonstrates that the combination of 
these two parameter, when optimised provides a better recovery of vitamin D compounds. 
The extraction conditions thus chosen were based on three-fold LLE extractions and the 
serum sample volume was chosen to be 500 µL in order to achieve the maximum potential 
recovery. 
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Figure 2.6: Signal responses for major vitamin D compounds during sample volume and 
extractions study 
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2.12 Optimisation of protein precipitation procedure 
2.12.1 Introduction 
Protein precipitation using acetonitrile was selected based on its high efficiency in 
precipitating proteins (213). Liquid-liquid extraction (LLE) is a relatively simple and the 
most common clean-up procedure used for the analysis of vitamin D compounds following 
protein precipitation. In this study, the sample preparation procedure was compared; protein 
precipitation with LLE and without LLE in combination with PTAD derivatisation followed 
by analysis using LC- MS/MS. The sample volume (500 µL) and number of LLE extractions 
(three times with total volume 1500 µL) were used as per the optimised method in section 
2.11. 
 
2.12.2 Sample preparation 
2.12.2.1. Protein Precipitation with liquid-liquid extraction (LLE) 
Serum (500 µL) was mixed with 1000 µL of acetonitrile, and 25 µL of combined internal 
standard solution (to give the same concentrations as those in calibration standards in the 
final solution injected onto LC-MS/MS), then vortex mixed for 1 min. The solution was 
incubated for 15 min at room temperature to allow protein precipitation to proceed to 
completion. The mixture was centrifuged at 4000 x g for 10 min, the supernatant transferred 
to a clean Eppendorf tube and evaporated under a gentle stream of nitrogen gas at room 
temperature to evaporate the majority of the acetonitrile.  
 
The remaining solution (approximate 500 µL) after the above procedure was extracted three 
times (using three equal aliquots of 500 µL) with a total volume of 1500 µL hexane: 
dichloromethane (4:1, v/v) and the solution was then vortex mixed for 1 min. Each of the 
upper, clear layer supernatants was collected and transferred to a new set of clean tubes and 
dried under a gentle stream of nitrogen gas at room temperature. The dry residue was then 
subjected to a derivatisation reaction with PTAD, as described in section 2.5 above. The 
derivatised mixture was evaporated to dryness under a gentle stream of nitrogen and the 
residue reconstituted in 50 µL mobile phase (77% B – section 2.6) before LC-MS/MS 
analysis. All preparations were done under subdued light. 
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2.13.2.2. Protein Precipitation without liquid-liquid extraction (LLE) 
Serum (500 µL) was mixed with 1000µLof acetonitrile, and 25 µL of combined internal 
standard solution (to give the same concentrations as those in calibration standards in the 
final solution injected onto LC-MS/MS), then vortex mixed for 1 min. The solution was 
incubated for 15 min at room temperature to allow protein precipitation to be completed. The 
solution was centrifuged at 4000 x g for 10 min, the supernatant transferred to a clean 
Eppendorf tube and evaporated under a gentle stream of nitrogen gas at room temperature to 
evaporate most of the acetonitrile. The remaining solution in each tube was then frozen at -
80°C for one hour, then evaporated to dryness using a freeze drier operated at -80°C (12 h). 
The dry residue was subjected to a derivatisation reaction with PTAD, as described in section 
2.5 above. The derivatised mixture was evaporated to dryness under a gentle stream of 
nitrogen and the residue reconstituted with 50 µL mobile phase (77% B – section 2.6) before 
LC-MS/MS analysis. All preparations were done under subdued light. 
 
2.12.3 Results and discussion 
Data were generated by extracting 10 individual human serum samples and Figure 2.7 shows 
the comparison between the protein precipitation method with LLE and without LLE. Protein 
precipitation with a subsequent liquid–liquid extraction (LLE) step shows evidence of 
vitamin D loss and no signals for any vitamin D sulfate compound (Figure 2.7). It was 
hypothesise that not all vitamin D compounds from the matrix were extracted during the 
liquid–liquid extraction step and that the extraction and/or LC-MS/MS method proved to be 
unsuitable for the sulfate compounds. However, using the original method of protein 
precipitation and by removing the LLE step, the vitamin yields for such lipophilic compounds 
improved and one sulphate analogue, 25(OH)D3 was recovered. 
 
The comparison study demonstrates that despite the lengthy drying process, protein 
precipitation without LLE resulted in high recoveries of vitamin D compounds. Taking into 
consideration the necessity of exploring assays for multiple compounds, all studies in this 
chapter then were carried out using the original protein precipitation method without LLE. 
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Figure 2.7: Comparison between protein precipitation with LLE and protein precipitation 
without LLE procedures using human serum samples. Mean concentrations of compounds in 
10 individuals shown. Error bars represent ±1SD. 
LLE, liquid- liquid extraction 
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CHAPTER 3: SIMULTANEOUS DETERMINATION OF 12 VITAMIN D 
COMPOUNDS IN HUMAN SERUM USING ONLINE SAMPLE PREPARATION 
AND LIQUID CHROMATOGRAPHY- TANDEM MASS SPECTROMETRY 
(LC- MS/MS) 
___________________________________________________________________________ 
3.1 Foreword 
The LC-MS/MS method described in Chapter 2 is capable of determining nine lipophilic 
forms and a single hydrophilic forms [25(OH)D3-S] of vitamin D. It failed to properly 
accommodate three other sulfate compounds [25(OH)D2-S, D3-S and D2-S]. This chapter 
continues improvements to the method and aims to develop a method for the quantification of 
12 vitamin D compounds simultaneously in human serum using liquid chromatography-
tandem mass spectrometry (LC- MS/MS). The main challenge encountered was that of 
extracting and chromatographing vitamin D compounds with a range of polarities, 
encompassing both lipophilic and hydrophilic, in a single analytical procedure. The chapter 
explores in detail the strategies devised to improve the efficiency of extraction and used 
careful pH control in order to produce adequate chromatography for both lipophilic and 
hydrophilic forms of the vitamin D compounds. The simplicity of the method was enhanced 
by removing the lengthy derivatisation procedure and incorporating an online solid phase 
extraction (SPE). Much work of this chapter has been published in the Journal 
Chromatography A, 2017; https://doi.org/10.1016/j.chroma.2017.12.012. However, to be 
compatible with the style and the flow of the thesis, some text and content modifications have 
been introduced.  
 
3.2 Introduction 
Recent literature has described contemporary mass spectrometry assays for the quantitative 
measurement of multiple vitamin D compounds and their application in clinical research (34, 
153, 214). It has been suggested that each member of the family of vitamin D compounds 
may have different functions beyond the traditionally referenced maintenance of 
musculoskeletal health towards conditions such as diabetes, cancer, multiple sclerosis, 
depression, and cardiovascular disease (52, 215). Consequently, the demand for 
measurements for vitamin D compounds in pathology laboratories has significantly 
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increased. Unfortunately, many studies investigating links between vitamin D and diseases 
investigate a single metabolic oxidative pathway, that yielding 25-hydroxyvitamin D 
[25(OH)D3 and 25(OH)D2], to assess the vitamin D status of individuals (216). It is plausible 
that measuring only 25-hydroxyvitamin D concentrations will provide an incomplete picture 
of vitamin D status that may or may not correlate with function or disease. An expansion of 
the range of vitamin D compounds that can be selectively quantified is hence potentially 
important for future vitamin D research. 
 
Ideally, a benchmark method for all vitamin D metabolites would cover the relevant high and 
low abundance compounds, and would use universal, standardised analytical techniques (34). 
Methods for the determination of lipophilic vitamin D compounds, especially 25(OH)D3, 
have been reported for a diverse range of biological fluids (23, 143). However, the lack of 
analytical methods for the determination of the more hydrophilic vitamin D compounds, such 
as the vitamin D-sulfate conjugate metabolites, has precluded their investigation in clinical 
studies examining their role and biological functions. While controversy exists regarding 
their biological roles, it has been reported that 25-hydroxy D3-sulfate [25(OH)D3-S] may be a 
storage form of vitamin D3 and knowledge of its concentration may be expected to be helpful 
in the assessment of the vitamin D status, especially that of infants (78).  
 
A previous method has been developed and is discussed in Chapter 2 above. The method uses 
derivatisation methodologies, to determine the major vitamin D compounds in human serum 
but was found to be inappropriate for the determination of three of the sulfated (D2-sulfate, 
D3- sulfate and 25-hydroxy D2-sulfate) vitamin D compounds (217). A separate, non-
derivatisation, method has also been developed to quantify these sulfated forms alone, taking 
into account their hydrophilic nature (84); both of these methods employed C18 columns. It 
was therefore resolved to undertake analytical method development to quantify 
simultaneously 12 vitamin D compounds including the sulfated forms [vitamin D2 and D3 (D2 
and D3), 25-hydroxy D2 and D3 (25(OH)D2 and 25(OH)D3), 24,25-dihydroxy D2 and D3 
(24,25(OH)2D2 and 24,25(OH)2D3), 1,25-dihydroxy D2 and D3 (1,25(OH)2D2 and 
1,25(OH)2D3), D2- sulfate and D3-sulfate (D2-S and D3-S) and 25-hydroxy D2-sulfate and D3-
sulfate (25(OH)D2-S and 25(OH)D3-S)] using a simple method with no derivatisation, 
incorporating some automation, and using a single column. The sensitivity was increased by 
reducing matrix effects in MS detector (using an additional sample clean up step) instead of 
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using pre-column derivatisation to improve ionisation in MS. The aim was to develop a 
method that was sufficiently simple and robust to accurately quantify 12 vitamin D 
compounds, both lipophilic and hydrophilic forms, using a single extraction and 
chromatographic run. The principal analytical challenge was that of quantifying compounds 
with very different lipophilicities in a single analysis procedure.  
 
Vitamin D levels are often analysed in plasma or serum samples. A recent study, reporting on 
the determination of nine vitamin D compounds, revealed that serum levels of vitamin D 
compounds were higher than those in plasma samples taken at the same time (217). Protein 
precipitation is a common approach used to release vitamin D compounds from serum or 
plasma binding proteins by using acetonitrile (ACN) or trichloroacetic acid (TCA) for protein 
denaturation (157). However, establishing which protein precipitation method would release 
more vitamin D compounds and thereby yield a chromatographically cleaner extract has not 
been studied to date. Protein precipitation does not remove phospholipids which can cause 
ion suppression in MS (thereby reducing sensitivity), can reduce HPLC column lifetime and 
increase the need for mass spectrometry maintenance due to contaminant build up on the ion 
source (218). A sample clean-up technique such as solid phase extraction (SPE) is required to 
remove phospholipids from the extract before it is subjected to chromatographic separation. 
However, such a SPE clean-up procedure necessitates additional time and effort in method 
development. In this chapter, two protein precipitation techniques have been compared, to be 
used as the initial sample preparation method to remove biological proteinaceous matrices. 
An on-line SPE method using a guard column was also introduced further to clean-up the 
extract prior to LC-MS/MS separation. Stable isotope labelled analogues of each targeted 
compound (twelve in total) were used as internal standards to correct for matrix effects in the 
MS detector as well as to correct for the procedural errors during sample extraction and clean 
up. No LC–MS/MS method has been reported which is able to quantify simultaneously the 
lipophilic and hydrophilic vitamin D compounds in human serum; as stated above, currently 
available LC–MS/MS methods for the determination of sulfated vitamin D compounds are 
limited only to the measurement of 25(OH)D3-S in human plasma (217)or separate 
quantification procedures are used for lipophilic and hydrophilic vitamin D compounds, 
respectively (84, 195). Hence, the aim of this study was to develop and validate a simple, 
effective and reliable method that can be used in a routine analytical laboratory to quantify all 
major vitamin D compounds (both lipophilic and hydrophilic forms) in human serum, 
providing good precision, accuracy and sensitivity. 
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3.3 Materials and methods 
3.3.1 Serum and plasma samples 
Blood samples were obtained from volunteer staff and research students (20 participants) of 
the School of Pharmacy, University of Queensland. Ethical approval was obtained from the 
Institutional Human Research Department, The University of Queensland. All volunteers 
provided written informed consent and relevant information such as the hours of exposure to 
sunlight during the week of interest, consumption of vitamin D supplements and the type. 
Serum samples were collected in vacutainer tubes without anticoagulant. Aliquots (500 µL) 
of the serum samples were accurately measured and frozen at -80°C until analysis. 
 
3.3.2 Chemicals and reagents 
All reagents, solvents, unlabelled standard and standard vitamin D compounds were 
purchased as described in Chapter 2. Trichloroacetic acid (TCA) and 4-methylmorpholine 
were purchased from Sigma Aldrich (St. Louis, MO, USA); 3-epi-25(OH)D3 and 3-epi-
25(OH)D3-d3 were purchased from IsoScience (King of Prussia, PA, USA). Figure 3.1 
shows the chemical structures for all stable isotope labelled vitamin D compounds (the 
analyte structures can be obtained by respectively replacing the deuterium atoms in each 
structural representation by hydrogen/ protium atoms). 
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Figure 3.1: Chemical structures of the deuterated analogues of vitamin D compounds used in the analysis 
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3.4 Preparation of standards solutions 
All preparations and manipulations of vitamin D containing solutions were done under 
subdued light. Stock solutions in ethanol of all standard compounds were prepared at a 
concentration of 1 µM, were sub-divided into small volumes, and stored in amber Eppendorf 
tubes at -20 °C. All working solutions were prepared by serial dilution of stock solutions. The 
combination standards contained the concentrations described in section 3.10 below. 
 
3.5 Preparation of sample solution and standard solutions prior to on-line SPE 
A frozen serum sample (500 µL) was thawed andspiked with 25 µL of the combined internal 
standard solution (to give the same concentrations as those in calibration standards in the 
final solution injected onto LC- MS/MS – as listed in section 3.10), 975 µL of acetonitrile 
was added, and then vortex mixed for 1 min. The mixture was incubated for 15 min at room 
temperature to allow protein precipitation to be completed, then centrifuged at 4000 xg for 10 
min. The supernatant (1100 μL) was transferred to a clean Eppendorf tube and mobile phase 
(75%B – section 3.9) added to a final volume of 1600 μL, and vortex mixed. The sample was 
injected using full loop mode with a 100 μL loop and overfill factor of 15.  
 
With standards, 500 µL of each of the six combination standards containing internal 
standards was mixed with mobile phase (75% B) to a final volume of 1600 µL and vortex 
mixed for 1 min before injection.  
 
3.6 Comparison of two solvents to release vitamin D from serum by protein 
precipitation 
The protein precipitation procedure used in this section was similar to our previous work 
(217). Briefly, an aliquot of serum (250 µL) was mixed with 500 µL of acetonitrile or 2% 
(w/v) trichloroacetic acid. The mixtures were vortex mixed for 30 s and then incubated for 15 
min at room temperature. Following protein precipitation, the mixtures were centrifuged at 
4000 x g for 10 min. The supernatants were transferred to clean Eppendorf tubes and 
evaporated to dryness using a freeze drier (12 h). The residues were reconstituted with 50 µL 
of mobile phase (75% B) prior to injection of 20 µL in LC-MS analysis. In this experiment 
the online sample clean-up was not used, and the extracts from two protein precipitation 
methods were directly injected to the analytical column. Triplicate measurements were 
performed and peak areas were used to assess the efficacy of each set of conditions. 
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3.7 Optimisation of mobile phase pH 
Mobile phases were prepared by varying the buffer in both the aqueous (solvent A) and 
organic (solvent B) component as described in Table 3.1. The pH values of the mobile phase 
solutions were measured using a Mettler Toledo Seven CompactTM S210 pH meter (Mettler 
Toledo, Switzerland); the pH meter was calibrated with buffer solutions of pH 4.00, 7.00 and 
10.00. All experimental settings were as per the optimised SPE method shown in section 3.8. 
Table 3.1: Mobile phases used in scouting experiments 
 
3.8 Optimisation of on-line solid phase extraction (SPE) and separation 
The optimisation of operating procedure was carried out using a combination standard 
prepared as in section 3.10. Guard column (SPE) and analytical column conditions were 
optimised separately, based on the highest peak areas and best peak resolution respectively. 
Parameters optimised were: stationary phase (PFP and C18), flow rate (0.2-1.2 mL/min), 
buffer (ammonium formate, 4-methylmorpholine) and mobile phase composition (25:75-
60:40 (water: methanol)) summarised in Table 3.2. The on-line clean-up and separation 
procedure used in this study is shown in Figure 3.2. 
  
Mobile phase/ 
pH 2.56 6.42 6.42 7.50 
Aqueous 
component 
(A) 
Water with 
0.01M 
formic acid 
Water with 5 mM 
ammonium 
formate 
Water with 5 mM 4-
methylmorpholine 
adjusted with formic 
acid 
Water with 10 
mM ammonium 
formate 
Organic 
component 
(B) 
Methanol 
with 0.01M 
formic acid 
Methanol with 5 
mM ammonium 
formate 
Methanol with 5 
mM 4-
methylmorpholine 
adjusted with formic 
acid 
Methanol with 
10 mM 
ammonium 
formate 
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Table 3.2: Optimisation of solid phase extraction (SPE) 
 
SPE Column 
 Variable  Tested variable 
Type PFP, C18 
Flow rate 0.2-1.2 mL/min 
Buffer Ammonium formate, 4-methylmorpholine 
Mobile phase composition (A) 25-40 % 
Mobile phase composition (B) 60-75 % 
  Analytical column 
 Variable  Tested variable 
Flow rate 0.2- 1.2 mL/min 
Buffer Ammonium formate, 4-methylmorpholine 
pH of mobile phase 2.56-7.50 
Mobile phase composition (A) 25-40 % 
Mobile phase composition (B) 60-75 % 
Temperature 30-40˚C 
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Figure 3.2:Scheme of the two valve positions (219); Flow shown in green 
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3.9 LC-MS/MS procedure 
An Agilent binary LC system consisting of an Agilent 1290 infinity LC pump and an Agilent 
1290 well plate auto-sampler was used. A pentafluorophenyl (PFP) guard column/ SPE 
column (2.1 x 5 mm, 2.7 μm; Agilent Technologies, Santa Clara, CA, USA) and PFP 
chromatographic column (150 x 2.1 mm, 2.7 μm (Agilent Technologies, Santa Clara, CA, 
USA) (column temperature 40 °C). were installed on the switching valve system as described 
in Figure 3.2. 
 
For sample clean up and for chromatographic separation (using pumps A and B) the same 
mobile phases were used: mobile phase A (aqueous 3 mM ammonium formate) and mobile 
phase B (methanol containing 3 mM ammonium formate). While operating in position A, the 
solid phase extraction (SPE) column (PFP guard column) was equilibrated with a mixture of 
the two mobile phases in a ratio A: B (60:40), at a flow rate of 0.8 mL/min (using pump A) 
for 10 min. Then the sample (1500 µL), obtained following protein precipitation, was 
injected onto SPE and washed for 2.5 min with the same conditions.  
 
During the period of SPE clean up, in position A, the analytical column was equilibrated 
using pump B with the two mobile phases in a ratio A:B (75:25) at 0.2 mL/min. After 2.5 min 
wash, the guard column was connected to the analytical column using the switching valve 
system to start the chromatography process (position B). The analytical mobile phase was 
maintained for 11.5 min at 75% B and the composition changed from 75% B to 100% B over 
the next 1 min, thereafter, it remained at 100% B for the next 9 min. The mobile phase was 
then returned to the starting composition of 75% B over the next 1 min, and the column was 
subsequently re-equilibrated with 75% B for 10 min before injecting the next sample. The 
total run time including the equilibration of the column was 35 min. During the 
chromatographic run, the SPE guard column was washed using 100% mobile phase B using 
pump A. 
 
An Agilent 6460 triple quadrupole tandem mass spectrometer equipped with a Jet Stream 
source and supported by Mass Hunter Workstation software (Agilent Technologies, Santa 
Clara, CA, USA) was used as the detector. For all compounds, the MS parameters were 
optimised to obtain the highest signal in MRM mode. The MS was used in dual polarity 
mode to detect all compounds in a single run: for all lipophilic vitamin D compounds (D2, D3, 
25(OH)D2, 25(OH)D3, 24,25(OH)2D2, 24,25(OH)2D3, 1,25(OH)2D2 and 1,25(OH)2D3), ESI 
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positive ion mode was used and ESI negative mode was used for the four sulfate compounds 
(D2-S, D3-S, 25(OH)D3-S and 25(OH)D2-S). Deprotonated species ([M−H]−) were selected 
as precursor ions for all vitamin D-sulfate compounds, whilst for lipophilic vitamin D 
compounds the protonated precursor ions ([M+H]+) or (M+H-H2O)+ were used. Table 3.3 
shows the optimised MRM transition parameters, the fragmentor and collision energy (CE) 
voltages and electrospray ionisation (ESI) mode used. Source parameters including gas flow, 
sheath gas flow, gas temperature and sheath gas temperature were optimised and maintained 
at 5 and 12 L/min (gas and sheath gas flows, respectively) and at 300 oC and 250 oC (gas and 
sheath gas temperatures, respectively). The capillary and nozzle voltages were maintained, 
respectively, at 5000 V and 2000 V. 
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Table 3.3:Optimised mass spectrometry parameters used in MS detection 
 
Vitamin D 
compounds  
MRM 
transition 
Qualifier ion 
(m/z) 
Fragmentor 
Collision 
energy  
ESI 
mode 
Precursor ion 
- Product ion  
(m/z) 
(V) (V) 
D3 385-159 162 104 24 Positive 
D3-d3 388-162 - 104 24 Positive 
D2 397-159 
 
100 43 Positive 
D2-d3 400-162 - 100 43 Positive 
Epi-25(OH)D3 401-159 257 100 28 Positive 
Epi-25(OH)D3-d6 407- 65 - 100 28 Positive 
25(OH)D3 401-159 257 100 28 Positive 
25(OH)D3-d6 407-165 - 100 28 Positive 
25(OH)D2 413-159 
 
90 24 Positive 
25(OH)D2-d6 419-165 - 90 24 Positive 
25(OH)D3-S  479-96 - 222 36 Negative 
25(OH)D3-S-d3 482-96 - 222 36 Negative 
25(OH)D2-S  491-96 - 222 40 Negative 
25(OH)D2-S-d3 494-96 - 222 40 Negative 
1,25(OH)2D3 417-399 381 124 4 Positive 
1,25(OH)2D3-d6  423-405 - 124 4 Positive 
D3-S  463-96 - 232 36 Negative 
D3-S-d3  466-96 - 232 36 Negative 
1,25(OH)2D2 –H2O 411-151 133 144 4 Positive 
1,25(OH)2D2-d6 417-157 - 144 4 Positive 
D2-S  475-96 - 242 36 Negative 
D2-S-d3 478-96 - 242 36 Negative 
24,25(OH)2D3 417-381 159 90 12 Positive 
24,25(OH)2D3-d3 420-384 - 90 12 Positive 
24,25(OH)2D2 429-393 111 60 4 Positive 
24,25(OH)2D2-d6 435-399 - 60 4 Positive 
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3.10 Method Validation 
The calibration range for each compound was determined based on previously reported 
concentrations in human serum. The calibration ranges (six levels) were as follows: 0.5-100 
nM [25(OH)D3, 25(OH)D2, D3, D2, 25(OH)D3-S, 25(OH)D2-S, D2-S, D3-S]; 0.05-2 nM 
[1,25(OH)2D3, and 1,25(OH)2D2]; 0.10-15 nM [24,25(OH)2D3 and 24,25(OH)2D2]. The 
internal standard concentrations in all calibration standards were: 50 nM [25(OH)D3, 
25(OH)D2, D3, D2, 25(OH)D3-S, 25(OH)D2-S, D2-S, D3-S]; 0.5 nM [1,25(OH)2D3, and 
1,25(OH)2D2]; 5 nM [24,25(OH)2D3 and 24,25(OH)2D2]. All calibration standards were 
prepared in mobile phase of the composition at the beginning of the gradient elution (75%B- 
section 3.9). Linearity was assessed by plotting the peak area ratios of standard/internal 
standard against the concentration of the standards using linear regression analysis.  
 
The limit of detection (LOD) was calculated as the concentration corresponding to three 
times the noise, and the limit of quantification (LOQ) as the concentration corresponding to 
10 times the noise, for each compound. Repeatability was determined by analysing 10 
separate aliquots of a pooled serum sample followed by the calculation of the percentage 
relative standard deviation for each vitamin D compound. Recovery was assessed by 
analysing the concentration of each vitamin D compound in six separate aliquots of spiked 
and non-spiked serum samples. Each aliquot of serum was spiked to give a final 
concentration similar to the level four of the calibration range used in this study. 
 
3.11  Results and discussion 
3.11.1 Optimisation of protein precipitation method 
The most efficient protein precipitants for protein removal have previously been reported to 
be acetonitrile and trichloroacetic acid (TCA) (157). These precipitants consistently removed 
plasma proteins effectively in samples from all species examined and at precipitant to plasma 
volume ratios of 2:1 (157). Figure 3.3 shows the peak areas obtained for each of the 12 
vitamin D compounds using the two protein precipitation solvents. Triplicate measurements 
were performed and peak areas were used to assess the efficacy of each set of conditions. In 
this comparison study, we were not able to detect three compounds, 25(OH)D2, 1,25(OH)2D2 
and 24,25(OH)2D2, using either extraction method due to their very low levels in the samples. 
For all other vitamin D compounds, the peak areas observed with TCA precipitation were 
only 1-6% of the areas observed with acetonitrile precipitation Protein precipitation with 
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acetonitrile was, therefore, seen to be more efficient in releasing vitamin D metabolites from 
the matrix and/or the acetonitrile extract is cleaner and therefore fewer compounds co-elute 
with the vitamin D peaks resulting in reduced ion suppression in MS detection (220). In 
general, it has been shown that improving the sample preparation and the chromatographic 
separation are the two most effective ways of circumventing ion suppression (196) in mass 
spectrometry.  
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Figure 3.3: Peak areas for 12 vitamin D compounds obtained after using the two protein 
precipitation solvents, acetonitrile or trichloroacetic acid (TCA) 
 76 
 
3.11.2 Effect of mobile phase pH: implications in liquid chromatography/tandem mass 
spectrometric bioanalysis for vitamin D –sulfate compounds. 
 
Mobile phase composition and pH in LC-MS/MS analysis are known to impact analyte 
ionisation, thus affecting the amounts and types of ions formed (221). Vitamin D-sulfates are 
acidic in nature due to the presence of the readily ionisable sulfate moiety, and are capable, 
by deprotonation, of producing negatively charged ions. A systematic investigation of the 
effects of mobile phase pH and organic modifier on ESI-MS response and chromatographic 
performance was assessed.  
 
The responses at pH (2.56-7.50) for vitamin D-sulfates in LC–ESI negative mode were 
compared, as noted in section 3.7. The use of a high-pH stable, highly efficient reversed-
phase HPLC column enabled the retention of the polar conjugate bases (sulfates). The 
principal mas ions detected were those of the protonated forms for the sulfate compounds. 
However, if ammonium adducts were to be formed between sulfates and ammonium ions in 
the mobile phase, the population of protonated form would thereby be reduced. When both 4-
methylmorpholine and ammonium formate were used in this experiment, a higher peak area 
for the protonated form with 4-methylmorpholine was observed if the compounds formed 
ammonium adducts. According to the data shown in Figure 3.4, the peak areas in panels C 
and D are similar, suggesting that no adduct formation is occurring. 
 
These results also show that pH affects the retention time and the peak response. Retention 
times increased at lower pH values. Based on the poor peak shape obtained and the long 
retention time at low pH (2.56), the low pH mobile phase with formic acid as the buffer was 
eliminated. Both the retention time and the peak response at pH 6.42 were favourable and 
therefore the mobile phase at pH 6.42, with ammonium formate buffer, was chosen for 
further studies. 
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Figure 3.4:Chromatograms illustrating the separation of D2-S, D3-S, 25(OH)D3-S and 
25(OH)D2-S,using varying pH and buffer conditions: (A) pH 7.50;water/ methanol with 
10mM ammonium formate (B) pH 2.56; water/methanol with 0.01M formic acid (C) pH 
6.42;water/methanol with 5mM ammonium formate  (D) pH 6.42; water/methanol with 5mM 
4-methylmorpholine adjusted with formic acid 
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3.11.3 LC-MS/MS method development for vitamin D compounds 
It is evident from the literature (157) that serum samples are not necessarily subjected to 
protein precipitation prior to using SPE. We have, however, reported here a simple manual 
protein precipitation step, to enhance the SPE recovery. The original methodology used in 
previous analytical method development involved a protein precipitation step similar to the 
method used in the chapter, the removal of acetonitrile using nitrogen, a subsequent 12 h 
freeze drying step followed by the derivatisation of the residual extract before injection onto a 
column (217). This lengthy, very labour intensive, sample preparation has now been replaced 
by a simplified off-line preparation involving manual protein precipitation which is then 
combined with an on-line SPE pre-treatment, equivalent to a trapping column technique, by 
using a re-usable guard column as the SPE column. The use of a relatively inexpensive guard 
column as a re-usable SPE cartridge has resulted in diminished operational and consumable 
costs and has significantly enhanced the lifespan of the analytical column. On-line two-
dimensional chromatography, using a column-switching device, has been previously shown 
to reduce matrix effects (202).  
 
The optimisation of the on-line clean up and separation was undertaken in two steps: the first 
stage focused on the extraction of the target compounds using the SPE guard column by 
injecting the combination standard of vitamin D compounds into the guard column and 
eluting directly to MS detector; the second stage focused on achieving best resolution of 
compounds by injecting the combination standard onto the complete assembly using a 1.5 mL 
sample loop.  The MS parameters were optimised by directly infusing the vitamin D standard 
solutions into the MS detector. The predominant product ion was used as the quantifier ion 
and another ion as the qualifier ion. 
 
There have been previous reports using a PFP column for underivatised vitamin D 
compounds (222-224). As derivatisation was omitted in this chapter for the reasons outlined 
above, a PFP analytical column was therefore used. It was also noted that the sensitivities for 
D-sulfate compounds were considerably enhanced at higher mobile phase pH values. 
Therefore, mobile phases were prepared using ammonium formate or 4-methylmorpholine. 
The reason for using 4-methylmorpholine was to prevent any possible adduct formation of 
some vitamin D compounds with ammonium ions. However, both mobile phases produced 
similar peak areas for all compounds, confirming that ammonium ions do not appear to form 
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adducts with vitamin D compounds at these conditions. Therefore, ammonium formate was 
used as the buffer in the optimised method. The chromatographic separation of 25(OH)D3 
from its 3-epi-25(OH)D3 isomer was necessary to enable quantification of these compounds 
since they have the same mass transitions. Optimisation of the chromatographic separation 
using different chromatographic gradients and column temperatures enabled the satisfactory 
resolution of these epimers. This agrees with previous studies that have achieved isomeric 
separation using PFP columns (26, 224-227). The PFP column uses a variety of separation 
mechanism; the interaction of the hydroxyl group of 3-epi-25(OH)D3 with the sorbent, allowed 
epimeric separation. The relative rigidity of the fluorinated bonded phase provides enhanced shape 
selectivity (288). 
 
Considering the ion-suppression effects of the buffer ions in mobile phase, it is desirable to 
use the lowest possible concentration of buffer in mobile phase. Therefore, the possibility of 
using a lower buffer concentration was examined by studying its effect on the 
chromatography of all the vitamin D compounds, using buffer concentrations 3mM and 5mM 
at pH 6. As there was no significant change in chromatography between the two 
concentrations, and there was an improvement in peak response, 3mM ammonium formate 
was selected as the optimum. 
The optimised flow rate, mobile phase composition and column temperature obtained are 
shown in Table 3.4. Chromatograms obtained for a standard mixture, using the optimum LC 
and MS conditions are shown in Figure 3.5. The aim of chromatographic optimisation was 
the separation of the epimeric form from 25(OH)D3 and to ensure that the chromatogram for 
the first peak of interest was satisfactorily remote from early eluting interfering compounds 
while achieving the separation of all compounds of interest within the shortest possible time. 
Table 3.4:Optimum condition of the automated SPE step 
 
Variable  
Optimum condition 
SPE Column Analytical column 
Type Pentafluorophenyl (PFP)  Pentafluorophenyl (PFP)  
Flow rate 0.8 mL/min 0.2 mL/min 
Buffer Ammonium formate Ammonium formate 
MP composition 40:60 (water: methanol) 25: 75 (water: methanol) 
Temperature 40˚C 40˚C 
pH 6.17 (3 mM ammonium formate) 6.17 (3 mM ammonium formate) 
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Figure 3.5: LC- MS/MS profiles of 12 vitamin D compounds (lipophilic and hydrophilic) in 
the standard mixture 
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3.11.4 Method validation and application to samples 
As shown in Table 3.5, the detection and quantification limits were found to be slightly 
higher, when compared to the previous method (217). These results may have arisen from the 
decision to remove the lengthy derivatisation procedure; the derivatisation enhanced the 
ionisation to a certain extent and additionally increased the signal/noise ratio since the 
analytes were detected at higher molecular masses where the noise from low molecular 
weight impurities in the mobile phase are reduced. As one of the main objectives of this 
chapter was to simplify the method by partially automating the sample preparation thereby 
making it suitable for routine analysis, the derivatisation step was removed. The lengthy 
multi-step derivatisation procedure used in vitamin D analysis (217) is not amenable to 
automation and therefore has not been fully or partially automated to date. The sample is 
required to be completely dry before derivatisation (188), and this is challenging to achieve in 
an on-line procedure.  
 
It has been clearly established that, when co-eluting, isotopically labelled analogues are used 
as internal standards, there is no significant difference in the results when the calibration 
standards are prepared either in mobile phase solvent or in matrix matched medium (211, 
212). Therefore, all samples and the calibration standards were prepared in mobile phase 
solvent at the same composition as the initial gradient conditions as described in LC-MS/MS 
section. The assay calibration demonstrated good linearities (R2> 0.99) for all 12 vitamin D 
compounds over the concentration ranges used. The concentrations of three of the vitamin D2 
compounds, 1,25(OH)2D2, 25(OH)D2-S and D2-S could not be reported, due to levels lower 
than the limit of quantification in the pooled serum sample used. The method was found to be 
precise with percentage standard deviations within the range 2.82-4.86%. The accuracy of the 
method, determined as the recovery values, ranged from 92% to 99%. The SD values 
reported in the recovery column of Table 3.5 gives an approximation of the precision for the 
three vitamin D2 compounds absent in the repeatability column. 
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Table 3.5:Linearity, repeatability, recovery, limit of detection and limit of quantification of all vitamin D compounds including epi-25(OH)D3 
 
 
Vitamin D 
compounds 
Linearity equation R2 
Repeatability (n = 10) Recovery (n = 6) 
*LOD (LOQ) ** LOD (LOQ) ***LOD (LOQ) 
Mean ± SD 
(nM)  
RSD 
(%) 
Mean ± SD (%) 
nM nM pmols 
25(OH)D3 y= 13.551x + 0.0314 0.9974 51.50 ± 1.48 2.87 97.6 ± 1.61 0.0367 (0.122) 0.117 (0.392) 0.0551 (0.184) 
epi-25(OH)D3 y= 4.8937x - 0.1135 0.9957 2.1200 ± 0.0686 3.23 97.9 ± 0.827 0.0367 (0.122) 0.117 (0.392) 0.0551 (0.184) 
25(OH)D2 y= 0.6559x + 0.2549 0.999 10.800 ± 0.341 3.17 97.8 ± 4.18 0.0121 (0.040) 0.0386 (0.129) 0.0181 (0.0603) 
D3 y= 0.0668x + 0.3179 0.9939 14.500 ± 0.627 4.33 92.5 ± 0.291 0.0188 (0.0628) 0.0603 (0.200) 0.0283 (0.0942) 
D2 y= 1.7506x - 2.1213 0.9968 2.230 ± 0.109 4.86 92.2 ± 1.26 0.0475 (0.158) 0.152 (0.507) 0.0713 (0.237) 
1,25(OH)2D3 y= 0.151x + 0.018 0.9902 0.6240 ± 0.0233 3.57 93.3 ± 0.0230 0.0239 (0.0796) 0.0764 (0.255) 0.0358 (0.119) 
1,25(OH)2D2 y= 2.1163x + 0.932 0.9905 N.D N.D 94.9 ± 0.0490 0.0680 (0.227) 0.217 (0.725) 0.102 (0.340) 
24,25(OH)2D3 y= 1.9274x - 0.966 0.9976 1.1200 ± 0.0357 3.18 93.2 ± 2.88 0.0179 (0.0598) 0.0574 (0.191) 0.0259 (0.191) 
24,25(OH)2D2 y= 5.6412x + 0.9608 0.9978 3.370 ± 0.120 3.6 96.1 ± 0.0430 0.0249 (0.0831) 0.0798 (0.267) 0.0374 (0.125) 
25(OH)D3-S y= 0.0076x + 0.1845 0.9904 12.000 ± 0.529 4.41 97.8 ± 0.667 0.0585 (0.1950) 0.187 (0.624) 0.0877 (0.292) 
25(OH)D2-S y= 0.1641x + 0.9365 0.9934 N.D N.D 95.7 ± 1.35 0.182 (0.606) 0.582 (1.939) 0.273 (0.909) 
D3-S y= 1.524x - 0.0496 0.9997 1.2000 ± 0.0338 2.82 99.7 ± 1.32 0.0255 (0.0849) 0.0814 (0.272) 0.0382 (0.127) 
D2-S y= 63.194x + 3.4594 0.9999 N.D N.D 97.3 ± 0.0690 0.0329 (0.109) 0.105 (0.351) 0.0493 (0.164) 
N.D, not detected; SD, standard deviation 
* Concentration in extract 
** Concentration in serum 
*** On column amounts 
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Table 3.6 shows the ranges of vitamin D compounds in donated human serum samples (n = 
10) collected from volunteers, using the optimised, validated method reported above. The 
lowest concentrations of vitamin D compounds were found in volunteers who: had not taken 
vitamin D supplements; did not use fortified vitamin D milk in their daily intake; and who 
were rarely exposed to sunlight in outdoor activities in the past two weeks. The above 
information was based on surveys provided by the volunteers prior to sample collection. A 
number of reports suggest that a 25(OH)D3 concentration below 20 ng/mL (50 nmol/L) (31, 
47, 58, 228) is an indication of vitamin D deficiency, whereas concentrations of 21–29 ng/mL 
(51–74 nmol/L) are considered to indicate insufficiency and concentrations of 30 ng/mL (75 
nmol/L) suggested by some to maximise the effect of vitamin D on calcium, bone, and 
muscle metabolism (228-230). Severe deficiency leads to rickets in children and osteomalacia 
in adults with concentrations of 25(OH)D3 below 10 ng/mL (25 nmol/L).The 
chromatographic profiles obtained for human serum are shown in Figure 3.6. The broadness 
of some peaks may likely to be due to incomplete separation of epimeric forms. The only 
epimeric form (separated) identified in this study, using a standard compound, is epi-
25(OH)D3. 
 
Table 3.6:Concentration ranges of vitamin D compounds in serum from 10 volunteers 
 
Vitamin D compounds Concentration ranges (nmol/L) 
25(OH)D3 18.7- 83.2 
epi-25(OH)D3 6.43- 47.0 
25(OH)D2 0.0654- 14.0 
D3 2.63 - 18.3 
D2 0.00- 3.65 
1,25(OH)2D3 0.263- 1.08 
1,25(OH)2D2 0.00- 2.62 
24,25(OH)2D3 0.264- 3.04 
24,25(OH)2D2 0.00- 0.159 
25(OH)D3-S 9.52- 43.8 
25(OH)D2-S 0.00- 40.0 
D3-S 0.0976- 2.75 
D2-S 0.00- 0.363 
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Figure 3.6: Chromatographic profiles showing 12 detectable vitamin D compounds 
(lipophilic and hydrophilic) in human serum samples  
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3.12 Conclusion 
This study is the first to report the development and validation of an analytical method for the 
simultaneous detection and quantification of 12 vitamin D compounds (both lipophilic and 
hydrophilic) in human serum. The high accuracy, selectivity and sensitivity obtained 
demonstrate the suitability of the proposed method for the determination of vitamin D 
compounds and their metabolites in man, that are potentially useful in disease diagnosis. The 
method described above has minimal sample handling; making it amenable for routine 
analysis. The method can be very likely applied to any biological fluid following 
modification of the sample preparation step. 
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CHAPTER 4: STANDARD ADDITION WITH INTERNAL STANDARDISATION TO 
ELIMINATE MATRIX FFECTS IN LC- MS/MS - APPLICATION TO VITAMIN 
D ASSAY 
___________________________________________________________________________ 
4.1 Foreword 
This chapter proposes an alternative approach for method calibration using standard addition 
with an internal standard. Traditionally, the standard addition method has been used to 
overcome matrix effects in atomic spectroscopy and has been a well-established method. This 
chapter proposes a similar application for mass spectroscopic detection following liquid 
chromatography and demonstrates that the results are comparable to those of the internal 
standard method using labelled analogues, for a vitamin D assay method. As the conventional 
standard addition procedure does not address procedural errors, the inclusion of an additional 
internal standard (not co-eluting) was proposed. Experiments were carried out in human 
serum and plasma samples. The internal standardisation approach using stable isotope 
labelled analogues (SIL-IS) results were compared with the proposed method of standard 
addition. Much of the work reported in this chapter has been submitted to the Analytical 
Chemistry journal. However, to be compatible with the style and the flow of the thesis, some 
text and content modifications have been introduced. 
 
4.2 Introduction 
According to the Union of Pure and Applied Chemistry (IUPAC) (231), a matrix effect is 
defined as the combined effect of all components of the sample other than the analyte on the 
measurement of the quantity while interference refers to the effect of a specific component 
that is identified as causing an effect on the measurement. When measurements are carried 
out in complex matrices such as blood, in which the composition varies from person to 
person, the effects on analytical measurement largely arise from matrix effects rather than 
interferences. Unlike with interferences, it is challenging to overcome matrix effects because 
of this variation in matrix composition. Ion suppression/enhancement is the most common 
form of matrix effect encountered in liquid chromatography–mass spectrometry (LC- MS), 
regardless of the sensitivity or selectivity of the mass analyser used (232, 233). A study by 
King et al.(234) indicates that the electrospray ionisation interface (ESI) is more likely to be 
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impacted in the manner when compared to atmospheric pressure chemical ionisation (APCI) 
(235). 
In general, matrix effects are due to inadequate sample clean-up, especially with complex 
sample matrices. However, with LC-MS, ion suppression is encountered even when there is 
no matrix by the trace impurities in mobile phase (236). Furthermore, sample clean-up 
procedures are designed to remove compounds that are dissimilar to the analyte therefore 
they cannot remove the compounds that are similar to the analyte that co-elute and cause ion 
suppression/enhancement in MS. Hence, the only option available is to correct the data for 
these matrix effects rather than trying to eliminate the matrix effects, by using appropriate 
calibration methods (154). The use of a stable isotope labelled analogue of analyte as internal 
standard (SIL-IS) is the generally accepted way of data correction for matrix effects, as it is 
most likely to completely co-elute with the analyte and to encounter the same amount of ion 
suppression/enhancement because it has almost identical chemical and physical properties to 
the target analyte (200). Furthermore, if added at the beginning of sample preparation, it will 
behave identically during all procedures as well as chromatography. However, it is important 
to recognise that a certain amount of ion suppression of the analyte will occur due to the co-
eluting isotope-labelled internal standard itself (233, 237). As the same amount of internal 
standard is added to all samples, ion suppression by the internal standard will affect samples 
containing smaller amounts of analyte to a greater extent. Furthermore, complete co-elution 
may not occur due to the slight change in lipophilicity of the molecule acquired during the 
replacement of the carbon bound hydrogen with deuterium (238), therefore the ion 
suppression effects may not be appropriately corrected. In some studies (239), it was found 
that there was significant difference in extraction behaviours (recovery) between the analyte 
and its deuterated analogue, that can also affect the accuracy of the data.  
 
In spite of the above-mentioned drawbacks, at present, the use of internal standard calibration 
using SIL-IS is the best option available to ensure the removal of matrix effects from LC-MS 
data. In practice, SIL-IS are generally very expensive and they are often not commercially 
available. Developing an LC-MS/MS assay for 12 vitamin D compounds (217) was an 
expensive exercise in consumable as some SIL-IS compounds were purchased and some were 
synthesised at a high cost. This and the knowledge of drawbacks described in the previous 
paragraph, prompted the exploration of alternative methods of overcoming matrix effects in 
LC-MS. 
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The standard addition method, taught through analytical chemistry text books as a calibration 
method to be used when matrix effects cannot be eliminated by physical means, has been 
widely used in spectrophotometric analysis, especially in atomic spectroscopy (240-243). 
Some atomic spectroscopic instruments such as graphite furnace AAS, are equipped with 
hardware and software to carry out the standard addition on-line. However, the method of 
standard addition has not been considered as a scheme for overcoming matrix effects in LC-
MS except for a few recent reports on its feasibility (154, 244, 245). 
 
The standard addition method of calibration employs exactly the same matrix in all 
calibration standards and therefore does not require matrix matched calibration standards. 
Matrix matching is an unachievable task in clinical analysis as the matrix will vary from 
sample to sample and thus differs from the matrix used for the preparation of calibration 
standards. In standard addition, each sample has its own calibration curve. Also, it is well 
suited for endogenous metabolite assays in biological fluids as there is no need for blanks and 
hence blank matrix in which to prepare calibration standards. The problems with SIL-IS 
methods as mentioned above, such as ion suppression by co-eluting internal standards or non-
co-elution due to the effects of dueteration are not present in the standard addition method. 
Most attractive practically is the absence of requirement to purchase or synthesise the 
expensive labelled compounds. The drawback is having to use at least three times the sample 
volume for analysis. With some prior validation work, the volume of sample used can be 
reduced to two-fold rather than three, by using a single addition calibration as described in 
the following discussion section.  
 
In this study, the possibility of operating the method of standard addition in routine LC- MS 
analysis to compensate for matrix effects was investigated by using a vitamin D assay as an 
example. The assay for vitamin D compounds used in this study is a good candidate as it 
simultaneously quantifies many compounds and is validated and well established method 
(246); vitamin D is also one of the most requested clinical assays in recent times (143). The 
classical standard addition method is not suitable for assays requiring multi-step sample 
preparation, as it does not compensate for procedural errors. Therefore, an internal standard 
was incorporated into the classical standard addition method and was then compared to the 
classical method. Coordination swapping (247) was also incorporated for ease and 
practicality. The accuracy of this improved, simplified standard addition method was 
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validated through the determination of recovery, and by comparison with existing method 
(using SIL-IS). 
4.3 Materials and Methods 
4.3.1 Chemical 
All reagents, solvents, unlabelled standard and standard vitamin D compounds were 
purchased as described in Chapter 2. 
 
4.3.2 Sample collection 
Blood samples were obtained as described in Chapter 3. 
 
4.4 Sample and standard preparation 
For all experiments, samples with known vitamin D compositions (based on prior analysis 
(246)) were used. For the comparison of methods, plasma samples previously demonstrated 
to be devoid of 25(OH)D2 were used; this enabled the use of 25(OH)D2 as an internal 
standard. The comparison studies used established methods using SIL internal standards 
(246) and those using standard addition (as described below in 4.4.2 but using all vitamin D 
compounds except 25(OH)D2 listed in 4.3.1 above in the combination standard added). The 
sample size used in all experiments was 250 µL for each extraction/run. 
For validation studies, a pooled sample of serum devoid of the target vitamin D compounds 
(D2 and 1,25(OH)2D2) and the internal standard (25(OH)D2) was used. In addition, a blank 
run was performed (using serum with no added vitamin D compounds) in 4.4.1 and 4.4.2 to 
ensure the absence of these compounds. From about 3.5 mL of the pooled serum sample, 250 
µL aliquots were pipetted for analysis as described in 4.4.1 and 4.4.2 below. To each aliquot, 
D2 and 1,25(OH)2D2 were added to mimic an original sample concentration of 5 nM and 0.5 
nM of each compound, respectively. These analytes were added at the first stage of extraction 
instead of adding to the pooled serum in order to avoid sample dilution. 
 
4.4.1 External standard calibration method (Method I) and stable isotope-labelled internal 
standard calibration method(Method II) 
A slightly modified version of the published method (246), using half the amount of sample, 
was used. To a 250 µL volume of serum sample, D2 and 1,25(OH)2D2 were added to give 
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concentrations of 5 nM and 0.5 nM of each, respectively, and the sample was then spiked 
with stable isotope-labelled internal standards (D2-d3 and 1,25(OH)2D2-d6) to provide final 
concentrations the same as those in the calibration standards. The mixture was thenvortex 
mixed for 1 min, and 500 µL of acetonitrile was added. The mixture was incubated for 15 
min at room temperature to allow protein precipitation to be completed and was then 
centrifuged at 4000 x g for 5 min. Supernatant (700 µL) was transferred to a clean Eppendorf 
tube and then mobile phase was added to obtain a final volume of 1600 µL. An aliquot of this 
extract (1500 µL) was injected to on-line solid phase extraction (SPE) followed by analysis 
using LC-MS/MS. The standards were prepared and processed as in the published method 
(246)but with only two vitamin compounds (D2 and 1,25(OH)2D2) and their corresponding 
SIL internal standards. There was a total of seven runs (sample run in triplicate and four-point 
calibration). The concentrations in each of the triplicate samples were calculated using: 
external standard calibration without using the internal standard responses (method I); and 
internal standard calibration (method II) (246). The recoveries were calculated using these 
concentrations and the added amounts (0.5 and 5 nM). 
 
4.4.2 Standard addition calibration method without (Method III) and with (Method IV) 
internal standard 
To a 250 µL volume of serum sample, D2 and 1,25(OH)2D2 were added to give concentration 
of 5 nM and 0.5 nM of each compound, respectively, and the sample wasspiked with the 
internal standard 25(OH)D2 to give a final concentration of 0.5 nM. A combination standard 
(D2 and 1,25(OH)2D2) was added to the sample to give two different levels of final 
concentrations (10 nM and 15 nM for D2, 1 nM and 1.5 nM for1,25(OH)2D2). Each of these 
levels were prepared in triplicate. The mixture was then vortex mixed for 1 min and then 
mixed with 500 µL of acetonitrile. The mixture was incubated for 15 min at room 
temperature to allow protein precipitation to proceed to completion and was then centrifuged 
at 4000 x g for 5 min. An aliquot of supernatant (700 µL) was transferred to a clean 
Eppendorf tube then mobile phase was added to obtain a final volume of 1600 µL. An aliquot 
(1500 µL) of this extract was injected to on-line solid phase extraction (SPE) followed by 
LC- MS/MS. There was a total of nine runs (three sample runs with no spiking, and six 
sample runs with spiking at two levels). With each of the triplicate samples, the concentration 
of the sample was calculated using the classical standard addition method by plotting the 
added concentration (0 nM, 5 nM and 10 nM) vs. peak area for each compound (method II), 
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with the concentration being the Y- axis intercept. The concentrations for the same samples 
were also calculated using the internal standard (25(OH)D2) – in this case instead of plotting 
the peak area as the X-axis, the ratio of peak area of analyte/internal standard peak area was 
plotted. Concentration was determined using the same approach as method III as negative Y-
axis intercept (method IV). The recoveries were calculated using these concentrations and the 
added amounts (0.5 and 5 nM). 
 
4.5 Results and discussion 
The chromatograms obtained for each of the compounds used in validation study are shown 
in Figure 4.1. A well-established method was used (vitamin D and metabolites) which has 
been previously validated and published (246), for this study. It was intended to validate the 
proposed standard addition method through recovery, hence, known amounts of two forms of 
vitamin D that were not present in the samples were added: D2 and 1,25(OH)2D2. The D2 
forms are present only in those individuals who consume plant-based vitamin D (143). As the 
dietary patterns of the volunteers had been previously collected, the serum from individuals 
who had no D2 forms in their blood could be pooled. In addition, blanks were run with each 
method performed to ensure the absence of these D2 forms. 
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Figure 4.1:Chromatograms for all vitamin D2 compounds and their deuterated compounds in 
human serum samples used in validation studies. 
The function of the internal standard used in the proposed method of standard addition is 
solely to correct for procedural errors and therefore there is no requirement for it to be 
structurally similar to the analytes, or to co-elute with the analytes. For convenience, another 
vitamin D2 form (25(OH)D2) was used as the internal standard since its chromatographic 
behavior was established and its absence in the samples used for this study had been 
previously demonstrated. However, any compound that elutes within the retention times of 
the analytes can be used for this purpose, as long as it will not be present in any sample. To 
use the vitamin D method (246) in standard addition mode, the most convenient approach is 
to use an isotopically labelled analogue of one of the vitamin D forms. With LC-MS/MS this 
can be separated from all analytes, and it is guaranteed to be absent in samples because it is a 
labelled compound. Because the labelled internal standard can co-elute with at least one of 
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the analytes of interest, and cause ion suppression it is best to use the labelled analogue of a 
compound that is less likely to be present and/or not of significant interest for quantification. 
Furthermore, it is advisable to check whether any other analyte of interest co-elutes with this 
internal standard and cause ion suppression. This is applicable for any assay for which 
sourcing of an internal standard that is absent in all samples is difficult to achieve. The 
internal standard will also be affected by the matrix effects in MS detection. However, the 
extent of this effect will be the same for all additions including the zero addition (zero in Y - 
axis in Figure 4.3 where the added standard concentration is zero) because the co-eluting 
impurities in the matrix is the same for all three additions. Therefore, the variation in peak 
areas of the internal standard will be due only to procedural errors but not to matrix effects. 
When the area of the analyte is divided by that of the internal standard in each chromatogram, 
this ratio is devoid of the procedural errors. Therefore, in this proposed method, this ratio is 
used in calibration rather than using area alone as is in the classical standard addition method. 
As with any internal standard calibration method, it is advisable to check the linear range of 
the internal standard and confirm that the response is linear within the variation expected 
(248). 
As described in 4.4.1 and 4.4.2, the same sample (containing known amounts of the two 
analytes of interest) was analysed (in triplicate each) using the external calibration (I), and 
internal standard calibration using SIL-IS (II). It was also analysed (in triplicate each) using 
the classical standard addition method (III), and the proposed standard addition method (IV) 
that incorporated an internal standard. 
With both methods III and IV, instead of plotting peak area (or peak area ratio of 
analyte/internal standard in proposed method) vs. concentration of the added standard 
(Figure 4.2), the reverse was plotted (Figure 4.3). This co-ordinate swapping method of 
standard addition calibration (247) is simpler than the classical method, as the concentration 
value is simply read as the negative value of the Y-intercept (rather than the ratio of the 
intercept and the slope with the classical method).  
 
Using the conventional linear equation below, where the independent variable standard 
added, X-axis (usually a concentration) and dependent variable, Y-axis (usually response or 
signal) (247). 
y = a0 + a1x  (Equation 1) 
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Ratio of the intercept (a0) and slope (a1) is the result of added amount for analyte; x0 = a0/a1. 
Figure 4.2 shows the direct regression calibration plot of the standard addition calibration 
method for both D2 and 1,25(OH)2D2 compounds.  
 
Figure 4.2: Direct regression of classical standard addition with internal standard calibration 
method. Concentration observed obtained from the equation, y = a0 + a1x 
where x0 = a0/a1 
 
However, in this chapter for the standard addition method, the concentration observed of each 
vitamin D compound in serum samples was determined directly using a calibration plot of 
concentration versus the peak area of each and analyte by using the Juris et al. coordinate 
swapping procedure (247) in inverse linear regression, x = b0 + b1y (247) (Figure 4.3). The 
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negative Y-intercept from the equation was hence the concentration of the respective vitamin 
D compound in human serum, x0,inv = −b0. Table 4.1 shows this method as applied to method 
IV, the proposed standard addition method in this study. 
 
Figure 4.3:The added concentration vs peak area ratio (analyte/internal standard) for the 
proposed standard addition method. 
The concentrations were determined as the negative intercepts: 4.77 nM for D2 and 0.479 nM 
for 1,25(OH)2D2. 
Table 4.1 shows a comparison of all four methods based on their recoveries. The recovery 
calculation was based on the known amounts added, and therefore a recovery of 100 indicates 
the highest accuracy. The extent of deviation from 100 in this study corresponds to the 
magnitude of matrix effects that were not removed from the data. The percentage recovery 
was determined using the following formula: 
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% recovery = Concentration of sample observed    × 100%                        
   Concentration of sample expected  
 
As expected, the external calibration (I) has the lowest accuracy as there was no correction of 
matrix effects. SIL-IS method (II) has high accuracy but the drawbacks discussed above in 
the introduction may be responsible for the slight loss of accuracy. The classical method of 
standard addition (III) has lower precision as well as accuracy when compared to the standard 
addition with internal standard (IV), mainly due to procedural errors rather than matrix 
effects. The proposed method of standard addition gives the highest accuracy. 
 
Table 4.1:Comparison based on recovery for four methods of calibrations (*n = 3) 
 
No
. 
Methods Compounds Concentration (nM) Recovery ± 
RSD (%)* 
      Expected  Observed 
I 
External standard 
calibration 
D2 5 4.12 82.4 ± 0.059 
  
1,25(OH)2D
2 
0.5 0.4 80.5 ± 0.102 
II 
Stable isotope labelled – 
internal standard (SIL-
IS) 
D2 5 4.56 90.7 ± 0.421 
  
1,25(OH)2D
2 
0.5 0.45 91.7 ± 2.17 
III 
Standard addition 
without IS 
D2 5 4.27 85.4 ± 3.85 
  
1,25(OH)2D
2 
0.5 0.47 94.6 ± 3.49 
IV 
Standard addition with 
IS (SA-IS) 
D2 5 4.77 95.2 ± 0.874 
    
1,25(OH)2D
2 
0.5 0.48 94.9 ± 2.62 
 
Quantitative analytical results for each vitamin D compound obtained by standard addition 
with the internal standard (SA-IS) calibration method were compared with the stable isotope 
labelled- internal standard (SIL-IS) calibration method. Table 4.2 shows the data for plasma 
vitamin D levels from three individual volunteers (1-3). Results were comparable proving 
that the proposed standard addition method (SA-IS) is an acceptable substitute to the SIL-IS 
method which is the gold standard in LC-MS for correcting matrix effects. 
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Table 4.2. Concentrations of 11 vitamin D compounds in plasma samples from three 
volunteers determined using standard addition with internal standard calibration method (SA- 
IS) and SIL-IS calibration method. *25(OH)D2 was used as internal standard for SA – IS 
calibration method. 
 
            
Compounds 
Concentration (nM) 
SIL-IS SA-IS (% difference from SIL - IS method) 
Sample ID 1 2 3 1 2 3 
25(OH)D3 14.5 17.2 16.01 14.8 (+2.16) 17.8 (+3.37) 16.1 (+0.37) 
25(OH)D2 
(IS) 
0.00 0.00 0.00 -- -- -- 
D3 0.047 1.29 3.20 0.0476 (+1.26) 1.36 (+5.43) 3.13(-2.34) 
D2 0.00 0.00 0.00 0.00 0.00 0.00 
1,25(OH)2D3 5.91 7.25 3.21 5.92 (+0.186) 7.45 (+2.69) 3.27 (+1.84) 
1,25(OH)2D2 0.00 0.00 0.00 0.00 0.00 0.00 
24,25(OH)2D3 5.66 1.22 3.59 5.69 (+0.440) 1.25 (+2.40) 3.60 (+ 0.278) 
24,25(OH)2D2 0.00 0.00 0.00 0.00 0.00 0.00 
25(OH)D3-S 2.33 2.22 4.21 2.38 (+1.92) 2.26 (+1.77) 4.08 (-3.19) 
25(OH)D2-S 0.00 0.00 0.00 0.00 0.00 0.00 
D3-S 0.00 0.00 0.00 0.00 0.00 0.00 
D2-S 0.00 0.00 0.00 0.00 0.00 0.00 
 
The major drawback with the standard addition procedure is the necessity of using three 
times the sample volume as compared to SIL-IS method. As Ellison and Thompson (249) 
highlighted, standard addition can only be precise and feasible when the analytical calibration 
curve is linear throughout the targeted concentration range. Therefore, this condition must be 
established prior to embarking on 2-point or 1-point standard addition procedure. 
 
4.6 Conclusion 
At present, internal standardisation using stable isotope labelled analogues of the analytes is 
the best available method to overcome matrix effects in LC-MS/MS. In this chapter, the 
problems associated with this method have been discussed and a standard addition method 
proposed as an alternative. The classical standard addition procedure is only suited to “dilute 
and shoot” type methods where the procedural errors are minimal. For others such as the 
vitamin D assay, as used in this study, we introduced an additional internal standardisation 
step to the classical standard addition method. Comparison with classical standard addition 
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and internal standardisation using SIL-IS showed that the proposed standard addition method 
in this paper to be a viable method to overcome matrix effects in LC-MS/MS. The accuracy 
of the proposed standard addition method was demonstrated to be superior to that of the SIL-
IS method. 
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CHAPTER 5: SAMPLE APPLICATION IN MOUSE BRAIN 
_________________________________________________________________________ 
5.1 Foreword 
This chapter will use the LC- MS/MS method developed in Chapter 3 above in the following 
application; the quantification of vitamin D metabolites in mouse brain tissue. The tissues 
samples were collected by Dr Virginie Lam from the School of Public Health, Faculty of 
Health Sciences, Curtin University, Perth, Australia and she was also involved in the 
experimental process and data analysis. The specific objective of this collaboration was to 
provide quantitative information on the concentrations of 12 vitamin D compounds in mouse 
brain samples using liquid chromatography-tandem mass spectrometry (LC- MS/MS). 
  
5.2 Introduction 
Some studies suggest that an inadequate dietary, essential vitamin, mineral or micronutrient 
supply of any number of such compounds can adversely affect brain function (250-252). One 
specific nutritional factor that has been linked to the epidemiology of Alzheimer’s disease is 
vitamin D. Alzheimer’s disease is a group of disorders characterised by neurodegeneration 
and progressive loss of memory and cognitive function (253). Moreover, epidemiological 
studies have shown significant associations between vitamin D deficiency and an increased 
risk of other various neuropsychiatric and neurodegenerative disorders in central nervous 
system function (254) and brain development in adults (255).  
 
There is also accumulating evidence that severely low serum 25-hydroxyvitamin D 
[25(OH)D] in adults is linked with a number of non-skeletal diseases. The report by Garcion 
et al. is of particular interest; accruing evidence relating vitamin D3concentrations and the 
brain function (256) and there are also suggestions that early developmental vitamin D3 
deficiency may be a risk factor for number of disorders associated with cognitive functions. 
Vitamin D3 has many effects on adult brain tissue, in vivo and in vitro (256), and there are 
suggestions (257) that early vitamin D3 deficiency may be a risk factor for the number of 
disorders relating to cognitive functions. The activating enzyme of vitamin D, 25-
hydroxyvitamin D31-alpha-hydroxylase, also known as cytochrome P450 27B1 (CYP27B1), 
is found in a wide variety of tissues throughout the body, including the brain (258, 259), 
along with 25-hydroxylase (CYP 2R1) and the enzyme required for the degradation of the 
biologically active form of vitamin D, 24-hydroxylase (CYP24A1) (260) (Figure 5.1). 
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Animal studies have shown that the vitamin D receptor (VDR) is also found within specific 
brain regions, including the hippocampus, amygdala, hypothalamus, thalamus, cortex, and 
cerebellum (261, 262), which are key areas for cognition (263). It is noteworthy that brain 
capillaries have significant expression of the VDR and of the enzyme 1-α-hydroxylase 
(CYP27B1), which converts 25(OH)D3 to the active metabolite, 1,25(OH)2D3. 
 
 
 
 
Figure 5.1: Representative diagram of synthesis and metabolism of vitamin D. 
Figure modified from Kalueff et al.(264) 
 
There was a growing evidence that vitamin D is involved significantly in mammalian brain 
functioning (265). A study based on brain tissue sample, found that vitamin D3 metabolites in 
brain tissue are significantly higher in rats fed with a vitamin D diet compared to rats fed a 
Vitamin D2/ D3 
Calcidiol (25(OH)D2 / 25(OH)D3) 
Calcitriol (1,25(OH)2D2 / 
1,25(OH)2D3) 
Target tissues: 
Brain, bone, kidney, chief cells 
Inactive metabolites: 
24,25(OH)2D2 / 24,25(OH)2D3 
1,24,25(OH)3D2 / 1,24,25(OH)3D3 
 
CYP27B1 
(1α-hydroxylase) 
CYP2R1 
(25-hydroxylase) 
Vitamin D receptor 
CYP24A1 
(24- hydroxylase) 
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deficient diet and serum and brain concentrations of vitamin D3 are strongly correlated (266). 
Therefore vitamin D3 status in serum directly affects bioavailability of vitamin D metabolites 
in brain. The majority of evidence concerning the biology and mechanisms of action of 
vitamin D in the brain, and most of the direct evidence for effects of vitamin D inadequacy on 
cognitive or behavioural function, rely on experiments conducted in laboratory rats or mice. 
A study by Feron et al. (267) demonstrated that vitamin D3 deficiency has profound effects 
on the developing brain including changes in volume, shape, cell proliferation and growth 
factor expression in rats.  Moreover, the nuclei of neurons in the certain brain regions of adult 
rats and mice have been found to contain 1,25(OH)2D3 (268). There is now also an 
accumulating evidence that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) is involved in brain 
development (267).   
 
A number of studies have summarised that vitamin D is synthesised in the skin of rats and 
humans (269, 270), and the distribution of the vitamin D receptor (VDR) in human and rat 
brains is very similar (271). The apoptotic effects of calcitriol on brain glial cells appears to 
be similar whether the cells are from humans or rats (272) and serum concentrations of 
vitamin D - binding protein are similar in laboratory rats and humans (273). A previous study 
showed that 25(OH)D3serum levels decreased in parallel to a similar decrease in 25(OH)D3 in 
brain tissue, whilst, 25(OH)D3in brain tissue increased with its level in serum in the 
supplement group (266). Furthermore, decreases in vitamin D metabolites in rat plasma from 
animals of advancing age were showed by Horst et al.(274). This, therefore, emphasises the 
potential importance of ensuring appropriate levels of vitamin D supplementation amongst 
older people both for maintaining bone health and also for improving cognitive performance. 
 
The aim of this study was to investigate the concentrations of 12 vitamin D compounds in 
mouse brain samples. The quantitative determination of vitamin D and its metabolites in 
mouse brain samples is a challenging task due to our present level of knowledge of such 
concentrations in the sample and the presence of interfering endogenous matrix materials.  It 
is likely that the findings from this study may be relevant to improve our understanding of the 
relationship between vitamin D concentrations and cognition in normal and pathological 
ageing, using cognitive tasks to assess specific cognitive processes. A developed and 
validated liquid chromatography mass spectrometry (LC-MS/MS) method for the analysis of 
a wide range of vitamin D analogues in serum was used to evaluate the level of D2, D3, 
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25(OH)D2, 25(OH)D3, 1,25(OH)2D2, 1,25(OH)2D3,24,25(OH)2D2, 24,25(OH)2D3, D2-S, D3-S, 
25(OH)D2-S, 25(OH)D3-S in the mouse brain samples. 
 
5.3 Materials and methods 
5.3.1 Brain samples 
Mouse brain samples were obtained from the Animal Resources Centre (Murdoch, Western 
Australia). Ethical approval and all experimental procedures were conducted in accordance 
with the requirements of the National Health & Medical Research Council accredited Curtin 
Animal Ethics Committee. Senescence- Accelerated- Mouse- Prone 8 (SAMP 8) and their 
age-matched controls, Senescence-Accelerated- Mouse- Resistant 1 (SAMR1) mice, were 
weaned at three weeks of age. Standard rodent chow (Specialty Feeds, Western Australia) 
and water were provided ad libitum to individually housed mice on a 12 h light/dark cycle 
(Curtin University Animal Facility). Both six-week and 52-weeks old male and female 
samples (n = 44) were analysed. 
 
5.3.2  Chemicals and reagents 
All reagents, solvents, unlabelled standard and standard vitamin D compounds used in this 
chapter were purchased as described in Chapter 2. 
 
5.3.3 Preparation of standard curves and linearity range. 
Stock solutions in ethanol of all standard compounds were prepared at a concentration of 1 
µM, were sub-divided into small volumes, and stored in amber Eppendorf tubes at -20 °C. 
All working solutions were prepared by serial dilution of stock solutions. The combination 
standards were further diluted in mobile phase to the appropriate concentrations for the 
preparation of calibration curves. To determine the linear range of the method, six levels 
(concentration level) of calibration were prepared and analysed as per samples. The 
concentrations of brain tissue standard curves used for all compounds were 0.5, 1, 4, 10, 20  
and 30 nM. 
 
5.3.4 Preparation of brain sample solution 
A sample (approximately 40 - 150 mg of snap frozen mouse brain tissue accurately weighed) 
was perfused prior to homogenisation in 1100 µL acetonitrile, vortexed for 30 s; the mixture 
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was then centrifuged at 4000 x g for 10 min. The supernatant was transferred to a clean 
Eppendorf tube and the mixture was vortex mixed for 30 s and mobile phase was added in 
order to obtain a final sample volume of 1600 µL. Samples of male (34) and female (10) 
mouse brain tissue were included in this analysis. 
 
5.4 LC-MS/MS method 
The samples were analysed according to the LC-MS/MS method used for the analysis of a 
range of vitamin D compounds as described in Chapter 3. Briefly, lipophilic and hydrophilic 
vitamin D compounds were measured using an online SPE method with simple protein 
preparation using acetonitrile prior to LC-MS/MS analysis. D2, D3, 25(OH)D2, 25(OH)D3, 
1,25(OH)2D2, 1,25(OH)2D3,24,25(OH)2D2 and 24,25(OH)2D3 were assayed using positive ion 
MS detection while D2-S, D3-S, 25(OH)D2-S, 25(OH)D3-S were quantitated using negative 
ion MS detection. 
 
5.5 Results and discussions 
In this study, calibration plots were derived by using the peak area of the target analyte and 
the concentration of each compound standard. Regression coefficients (R2) were above 0.99 
for all linear calibration models. Table 5.1 shows the average of vitamin D compounds in the 
overall mouse brain sample (n = 44) collected from male and female mice, using the 
developed and validated method reported in Chapter 3, while a representative 
chromatographic profile obtained for detectable vitamin D compounds in the mouse brain 
samples is shown in Figure 5.2.To our knowledge, this study was the first to attempt to 
detect and quantitate vitamin D sulphate metabolites in mouse brain; we observed, however, 
that sulphate forms were not present in any of the samples analysed. We consider that the 
absence of D2-S, D3-S, 25(OH)2D3-S and 25(OH)2D2-Sis due to the potential impact of the 
blood-brain barrier (BBB) on the transportation of sulfate metabolites into the cerebrospinal 
fluid. The BBB is a physical and biochemical barrier between the blood and the brain, which 
prevents entry into the brain of most drugs and endogenous compounds from the blood. Only 
small lipophilic compounds can diffuse passively through the BBB, while other compounds 
are usually able to cross the BBB only with the help of carrier proteins (275).  
Our results showed that membrane vitamin D3 receptors have also been identified in the brain 
and the concentrations of 1,25(OH)2D3 in the mouse brain tissue samples is markedly higher 
than that of other metabolites. This metabolite is able to cross the blood-brain barrier and 
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bind to nuclear vitamin D3 receptors in the brain (276, 277). In comparison to human serum 
concentrations, 1,25(OH)2D3levels in mouse brain were observed to be greater. It has been 
shown that a physiological concentration of the concentration in brain tissue of 25(OH)D3 
was five percent or less than that of 1,25(OH)2D3 due to their polarity differences (278). 
Owing to the added sulfate group, the polarities of D2-S, D3-S, 25(OH)D3-S and 25(OH)D2-
Sare likely greater than the polarity of lipophilic compounds – this is seen with other sulphate 
metabolites (279). Thus, it might be expected that the concentrations of vitamin D-sulfate 
compounds would be much reduced or indeed undetectable. This is possibly one of the main 
reasons that vitamin D-sulfate levels in brain tissue are largely unexplored and almost never 
measured in clinical practice. 
Table 5.1:Average concentration of vitamin D compounds in mouse brain tissue 
 
Compound 
Average concentration (nmol/kg) (n = 44) 
Male (n = 34) Female (n =10) 
25(OH)D3 3.78 2.87 
1,25(OH)2D3 23.3 23.1 
24,25(OH)2D3 12.2 9.37 
D3 19.3 19.5 
D2 11.7 8.02 
25(OH)D2 2.52 2.67 
1,25(OH)D2 9.81 11.4 
24,25(OH)2D2 5.63 4.16 
 
 105 
 
 
Figure 5.2:Chromatographic profiles showing eight detectable vitamin D compounds 
(lipophilic and hydrophilic) in mouse brain samples 
 
  
 106 
 
The concentrations of vitamin D compounds in brain tissues from mice at six weeks of age 
and 52 weeks of age were compared and the results shown in Figure 5.3; these samples, 
although revealing much inter-individual variability suggest an aged-associated decrease in 
brain concentrations of these compounds. Results in Figure 5.4 shows that the sex of the 
animal was not linked to statistically significant differences in vitamin D compound 
concentrations. Although the lack of correlation is clear it is possible that this can be 
explained by the relatively small sample number, male (n = 34) and female (n = 10), coupled 
with observed large inter-individual variations, in this study. Therefore, sex differences in the 
susceptibility to vitamin D deficiency should be explored further. 
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Figure 5.3:Level of eight vitamin D compounds in mouse brain of 44 samples for both sexes 
aged six weeks and 52 weeks. Bar graph represents mean and error bars indicate standard 
deviation 
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Figure 5.4:Sex difference did not lead to statistically significant differences in vitamin D 
compound concentrations. Results are presented as mean ± SD. There was no statistical 
difference found in the concentration ranges between male and female samples. 
 
In summary, the present data clearly demonstrate that the developed method to determine 
vitamin D metabolites in human serum is appropriate to use for mouse brain tissue samples, 
with a simple modification of the sample preparation step. We have shown sex differences in 
the susceptibility to vitamin D deficiency that should be explored further. Furthermore, 
research in animals that combines vitamin D deficiency with relevant animal models of 
neuropsychiatric and neurodegenerative disorders is also required. In addition, this 
collaborative study was able to provide the accurate detection and subsequent quantification 
of 12 vitamin D compounds, previously been determined by the ELISA kits-based method 
(280), which is unable to separate measure D2 and D3 compounds. Furthermore, with the 
extensive links between each level of vitamin D compound deficiency and other brain 
disorders now evident, there is a need for relevant animal models of neuropsychiatric and 
neurodegenerative diseases. 
 
5.6 Conclusion 
Mounting evidence suggests that maintaining optimal vitamin D levels may lower the risk of 
developing a wide range of brain disorders, this indicates that research focusing on the 
elucidation of the mechanisms of vitamin D’s actions within the brain will be of significant 
utility. The developed LC-MS/MS method has proved to be highly sensitive, specific, and 
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accurate in the quantitation of vitamin D compounds in animal brain tissue. If these 
observations in mice are relevant to humans, they may have important implications for public 
health. This study has provided preliminary data that can be used to predict the levels of 
vitamin D compounds in brain tissue in the developing and ageing adult human brain. Further 
research work is required to establish the biological implications related to these findings. 
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CHAPTER 6: GENERAL DISCUSSION AND CONCLUSION 
6.1 Foreword 
This chapter provides a summary and discussion of the main findings of the studies reported 
in this thesis. The thesis comprises two papers that have been published (Chapter 2 and 
Chapter 3) and one chapter (Chapter 4) submitted for publication. The limitations of the 
thesis are addressed and the implications for future research are present. 
6.2 Summary 
The primary goal of the studies presented in this thesis was to bring about advances in the 
field of vitamin D assays for biological sample especially for human blood samples, by 
developing a highly specific and sensitive LC-MS/MS method. This research started with the 
following specific aims :- 
• To develop a sensitive, accurate and robust LC-MS/MS method for the determination 
of 12 vitamin D compounds (D2, D3, 25(OH)D2, 25(OH)D3, 1,25(OH)2D2, 
1,25(OH)2D3, 24,25(OH)2D2, 24,25(OH)2D3, D2-S, D3-S, 25(OH)D2-S and 25(OH)D3-
S). 
• To compare the efficiencies of two different sample preparation methods (protein 
precipitation and saponification). 
• To determine the appropriateness of the biological sample (serum and plasma) as the 
sample to be used for vitamin D analysis and the sample size necessitated in order to 
measure simultaneously 12 vitamin D compounds in serum and plasma. 
• To develop a method that is amenable for routine analysis. 
• To apply the method to quantify the total vitamin D compounds in other biological 
fluids/matrices. 
 
Vitamin D now has been reported have many biological functions in humans beyond that 
relating the skeletal system (5). While there are more than 50 vitamin D metabolites, vitamin 
D status is usually evaluated by determining the plasma or serum concentrations of the 
metabolite 25-hydroxyvitamin D (25(OH)D3 and 25(OH)D2), the major circulating 
compound(s), considered to be a marker for vitamin D (281). However, it is still controversial 
as to whether the measurement of 25(OH)D alone provides sufficient information to link 
vitamin D with many other skeletal and non-skeletal disorders (34, 48). The ability to 
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quantify individual vitamin D form is essential in both nutritional and clinical samples in 
order to diagnose affected individuals who can receive appropriate treatment (143). In 
addition, early detection of vitamin D deficiency for new born babies is important; putting 
them at risk of long-term physical deficits. 
 
Each vitamin D compound has a different function in the body (11, 78, 225). Most biological 
actions of vitamin D are attributed to the metabolite 1,25-dihydroxyvitamin D (1,25(OH)2D3 
and 1,25(OH)2D2) that is, they are primarily responsible for preventing skeletal and non-
skeletal disorders (11, 282). The metabolites 24,25-dihydroxyvitamin D (24,25(OH)2D3 and 
24,25(OH)2D2) have also been found to play a crucial role in intramembranous and 
endochondral bone formation and in bone fracture repair (11). 3-Epi-25(OH)D3is considered 
as inactive vitamin D compounds and, therefore, the collective measurement of the vitamin D 
forms and their epimers may contribute to an overestimation of the 25(OH)D level (22). 
Vitamin D can be also found as hydrophilic forms (vitamin D2-sulfate (D2-S), vitamin D3-
sulfate (D3-S), 25(OH) D2-sulfate (25(OH)D2-S) and 25(OH)D3-sulfate (25(OH)D3-sulfate) 
(84). Hence, the capability to specifically measure a range of different vitamin D forms is 
highly valuable to investigate clinical disorders and their potential linkages to vitamin D 
status (34). 
 
Traditionally, immunoassay methods have been applied for the determination of vitamin D in 
biological fluid samples (283, 284). The main disadvantage is their incapability to 
differentiate between a number of the different forms of vitamin D(149). Liquid 
chromatography (LC) methods have also been used for the analysis of vitamin D compounds 
in biological fluids. The LC methods have an advantage over immunoassays because of their 
ability to distinguish a variety of vitamin D compounds in a single run with electrochemical 
(EC) (285) and ultraviolet (UV) (22, 155) detectors. However, recently tandem mass 
spectrometry (MS/MS) detection has been the method of choice not only due to its ability to 
accurately quantify multiple analytes in a single but its superior sensitivity, specificity and 
reproducibility. Nevertheless, poor ionisation efficiency of vitamin D compounds in the 
atmospheric pressure ionisation (API) source in LC-MS/MS analysis, and vitamin D being 
present in low levels in biological fluids have been drawbacks (143). 
In order to overcome the sensitivity issue, a derivatisation process based on the Diels-Alder 
reaction has been used to improve in signal response and increase in sensitivity of vitamin D 
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over the non-derivatisation assay method (187). Derivatisation with 4-phenyl-1,2,4-
triazoline-3,5-dione (PTAD) has proven to enhance the ionisation efficiency for small sample 
volumes such as neonatal biological fluids which the concentrations are too low to be 
detected by standard LC-MS/MS methods (23, 286, 287).  
Another challenge in vitamin D assays has been the extraction of vitamin D compounds, 
particularly in biological samples. Vitamin D compounds in biological fluid samples are 
tightly bound to proteins and lipids and it is necessary to disrupt this binding to release the 
vitamin prior to LC-MS/MS analysis in order to generate free compound for analysis and to 
avoid matrix effects (143, 153). Therefore, sample preparation includes all processes that are 
involved prior to separation and detection including extraction and clean-up, and is important 
in initial stage method development as it frequently improves on the accuracy of the 
analytical method. Furthermore, sample clean-up directly effects the sensitivity and 
selectivity of the assay and in addition, adequate sample clean-up protects the 
chromatographic columns and also reduces matrix effects from co-eluting substances during 
the ionisation process. Protein precipitation is often used to remove proteins from biological 
fluids while saponification is commonly used with foodstuffs (143). After protein 
precipitation or saponification processes, the sample requires further extraction in order to 
remove other interfering substances prior to separation and/or detection. Liquid-liquid 
extraction (LLE) and/or solid phase extraction (SPE) are widely used for the extraction 
procedure in vitamin D analysis. This combination of sample clean up and extraction has 
resulted in high throughput methods.  
Ion suppression/enhancement is the most common form of matrix effect occurred in liquid 
chromatography–mass spectrometry (LC- MS), when compounds that co-elute with the 
analyte interfere with the ionisation process, regardless of the sensitivity or selectivity of the 
mass analyser used. The only option to obtain accurate data is by complete elimination of the 
interfering compounds that co-elute with the analyte. The inclusion of stable isotope labelled- 
internal standard (SIL-IS) in the sample is able to remove the contribution from the 
interferences at the quantification step. SIL- IS calibration methods has become the most 
commonly used method to correct for matrix effects in MS detection (211) as SIL-IS are 
almost identical to those of the analyte, and they elutes at the same retention time as the ana-
lyte and experiences the similar extents of matrix effects. 
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The main objective of the research presented in this thesis was to develop an analytical 
method to measure quantitatively a wide range of vitamin D compounds, thereby creating a 
comprehensive picture of vitamin D status. Of particular focus is the simultaneous detection 
and quantification of 12 vitamin D compounds (both lipophilic and hydrophilic) in biological 
samples. The selected compounds comprised D2, D3, 25(OH)D2, 25(OH)D3, 3-epi-25(OH)D3, 
1,25(OH)2D2, 1,25(OH)2D3, 24,25(OH)2D2, 24,25(OH)2D3 (the lipophilic forms), vitamin D2-
sulfate (D2-S), vitamin D3-sulfate (D3-S), 25(OH) D2-sulfate (25(OH)D2-S) and 25(OH)D3-
sulfate (25(OH)D3-S) (the hydrophilic forms).  
 
Chapter 2 described initial method development and validation attempts of a simultaneous 
determination method of 12 vitamin D compounds in human blood using pre-column 
derivatisation and the separation by using C18 column. Serum (compared to plasma) was 
found to be a more suitable sample type, and protein precipitation (compared to 
saponification) a more effective extraction method. Only nine out of twelve compounds were 
detected in serum; the methods were only able to determine one hydrophilic compound, 
25(OH)D3-S, in human serum. This was not only because the presence of very low levels in 
serum but also arose due to the derivatisation process, the procedure proving unsuitable for 
sulfated compounds. The main challenge was that of extracting and chromatographing 
vitamin D compounds with different polarities, both lipophilic and hydrophilic, in a single 
analytical procedure.  
 
Additional assay method approaches were studied in Chapter 3; ammonium formate (at pH 
6.17) was used as the optimised mobile phase to facilitate the protonation (positive mode) 
and de-protonation (negative mode). The extraction of all 12 vitamin D compounds was 
achieved by an optimised protein precipitation method using acetonitrile as the precipitant. 
The sensitivity was improved by minimising matrix effects in the MS detector rather than by 
using a lengthy derivatisation procedure; an online solid phase extraction (SPE) using a 
pentafluorophenyl (PFP) guard column was used for clean-up and the separation was 
accomplished by using a PFP analytical column. A combination with the SPE method 
resulted in a significant simplification of the sample preparation procedure, the on-column 
detection and quantification limits were found to be somewhat slightly higher, when 
compared to the previous method of Chapter 2.LC-MS/MS resolution of all 12 vitamin D 
compounds, including the chromatographic separation of 25(OH)D3 from the isomer 3-epi-
25(OH)D3 was achieved. Stable isotope labelled vitamin D compounds were used as internal 
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standards for the quantification of all 12 vitamin D compounds in both methods outlined in 
Chapters 2 and 3. The method can be very likely applied to other biological fluids; mouse 
brain samples were also similarly analysed following modification of the sample preparation 
step, as described in Chapter 5. 
 
Developing the LC- MS/MS method for 12 vitamin D compounds can be a financially 
expensive exercise, in laboratory consumable terms, as SIL-IS compounds are required for 
each of the 12 vitamin D compounds. In order to develop a method combining assay utility 
with cost-effectiveness, the developed online method was then applied to study alternatives to 
the stable isotope labelled – internal standard (SIL-IS) calibration method, in which a 
standard addition method was combined with an additional internal standard (not co-eluting) 
to correct for procedural errors. Experiments were carried out on biological human 
plasma/serum samples. The results obtained show that the proposed method of standard 
addition yields more accurate results than internal standardisation using stable isotope 
labelled analogues, based on the recovery results shown in Chapter 4. 
 
In Chapter 5, the method was demonstrated to be easily adapted for other complex matrices 
such as exist in mouse brain tissue samples. Evidence continues to accumulate, indicating 
that adequate levels of vitamin D are required for normal brain development and function. In 
this study, it was confirmed that the vitamin D compound presence in mouse brain samples is 
significantly not extant in the sulphated forms, but concentrations of 1,25(OH)2D3 in mouse 
brain sample were markedly higher than the major metabolites, 25(OH)D3. While mindful of 
the limitations of analysis of sulfate forms, such findings may also prove useful for directing 
the association between a patient’s vitamin D levels with diverse clinical neurological 
outcomes. If these observations in mice are relevant to humans, they could have important 
implications for public health. 
 
Overall, the studies reported in this thesis have resulted in the development of LC-MS/MS 
methods for the successful determination of 12 vitamin D compounds (both lipophilic and 
hydrophilic in nature) in biological samples. The high specificities and sensitivities obtained 
demonstrate the suitability of the developed methods for the determination of vitamin D 
compounds and their metabolites in human samples, thus providing results that are 
potentially useful in disease diagnosis. These methods will therefore enable researchers to 
study more precisely the activities and functions of each vitamin D compound and the total 
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amount (and activity) of vitamin D in blood and other biological samples, which is of key 
importance in the investigation of links between vitamin D and clinical disorders. 
 
6.3 Study limitations 
The limitations of the studies were discussed in detail in each chapter. In summary, the initial 
developed method in Chapter 2 was time-consuming and was not best suited for routine 
analysis application. The studies reported in Chapter 3, permitted the elimination of 
derivatisation reactions by careful adjustment of pH and then the simplification of sample 
preparation procedures by partially automating the sample preparation method. The detection 
and quantification limits subsequently obtained were found to be somewhat higher when 
compared to the first developed method using a derivatisation step. The lengthy multi-step 
derivatisation procedure used in vitamin D analysis is not easily amenable to automation and 
therefore has not been fully or partially automated so far. The sample is required to be 
completely dry before derivatisation, and this is challenging to achieve in an on-line 
procedure.  
6.4 Future research directions 
The analytical methods presented in this thesis represent significant improvements upon 
existing methodologies. Multi- compound determination is one of the most important trends 
to provide a better diagnostic picture of vitamin D status. Further studies are also necessary to 
develop a method in order to fulfil the multi-compound determination of vitamin D 
metabolites with simple solid-phase separation procedures coupled to on-line derivatisation 
reactions. These represent assay necessities on the pathway to sample analysis automation - 
to decrease the complexity of the clean-up and increase the sensitivity with the required 
smaller sample size. Further research work is additionally required to advance the automation 
of sample preparation procedures, in order to fulfil the demand for high-throughput analysis 
techniques and making it suitable for routine analysis. 
The analytical method developed and implemented in this thesis can be applied to future 
research examining vitamin D in other biological fluids. With further development, an 
extended range of vitamin D compounds could also be studied including vitamin D-
glucuronide metabolites. It has been demonstrated that conjugation with glucuronic acid 
plays a quantitatively important role in the enterohepatic circulation of vitamin D. Future 
studies may focus on linking vitamin D-glucuronide status in brain development and 
function. Similarly, steroidal sulfates are known to undergo a variety of important 
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physiological roles, but the roles remain controversial. Further research work is required to 
better understand this class of vitamin D compounds. It would therefore be of clinical interest 
to investigate whether 25(OH)D3-S could be epimerised, as it could be a potential vitamin D 
marker. Also, it would be of greatest interest to investigate whether there are dihydroxy-
vitamin D compounds present as the respective sulfate conjugate.  
The development of vitamin D Standard Reference Material (SRM) is undertaken by the 
National Institute of Standards and Technology (NIST). Currently SRM 972a is only 
available for the following vitamin D compounds: 25(OH)D3, 25(OH)D2, 24,25(OH)2D3 and 
3-epi-25(OH)D3 with different levels of endogenous vitamin D metabolites in human serum. 
In the future, it may be appropriate, and indeed valuable, to compare a comprehensive SRM 
(ideally with all 12 compounds) against the method reported here.  
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6.5 Conclusion 
There are a number of strengths identified from the studies reported in this thesis. The thesis 
provided original contributions to the current knowledge in several ways. Firstly, a simple 
and effective method to simultaneously determine 12 vitamin D compounds in biological 
fluid was established. The concentration profiles of D2, D3, 25(OH)D2, 25(OH)D3, 
1,25(OH)2D2, 1,25(OH)2D3,24,25(OH)2D2, 24,25(OH)2D3, D2-S, D3-S, 25(OH)D2-S, 
25(OH)D3-S, both lipophilic and hydrophilic, in a single analytical procedure were then 
documented. Following this, the concentrations of these metabolites in human serum and 
mouse brain were examined. This thesis found that serum was a more suitable sample type 
when compared to plasma and protein precipitation was the more effective extraction method 
for vitamin D assay; protein precipitation with acetonitrile proved more efficient in releasing 
vitamin D metabolites from the matrix when compared to trichloroacetic acid. This thesis has 
provided new evidence that an additional internal standard (not co-eluting), when combined 
with a standard addition method can be effectively used to correct for procedural errors. 
Recoveries determined on human serum samples show that the proposed method of standard 
addition yields more accurate results than the internal standardisation using stable isotope 
labelled analogues. In mouse brain samples, concentrations of 1,25(OH)2D3 were higher, 
when compared to other metabolites (e.g. 25(OH)D3), whereas sulfate compounds were not 
detected. In summary, this thesis reported an original analytical method to analyse 
simultaneously 12 vitamin D compounds in biological fluids by using the most advanced and 
sensitive analytical technique available to date, for both lipophilic and hydrophilic 
compounds. 
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